the 7th annual meeting of the middle-eastern association for cancer...

Gaziantep University

Under the patronage of the Rector Prof. Ali Gür

21st and 22nd of December 2017

The 7th Annual Meeting of the

Middle-Eastern Association for

Cancer Research

Cancer Research from Basic Science to Clinic

Welcome Message from The President

of the 7th Annual Meeting of the MEACR

Dear colleagues,

Welcome to the 7th Annual Meeting of the MEACR in Gaziantep, Turkey. Our

colleagues from many countries participated in this conference, and I’m sure this

will be a successful event particularly with the number of oral presentations and

posters, that will be available at the meeting.

I believe that this meeting will provide a good opportunity for cooperation

between the various units of the University of Gaziantep and our colleagues

from universities worldwide, including Qatar University and the its college of

medicine. Particularly, given the obvious need for cooperation in the Middle East

region, I am happy to welcome you all in Gaziantep, the city that boasts with its

5,000 years of history. Our city is well known for its historical sites, rich cuisine

and hospitality that will make you leave with very nice memories.

The University of Gaziantep, Faculty of Medicine, is one of the pioneering

universities in national and international platforms in education, research and

health services. Our Faculty of Medicine has 1700 students with 220

international students from 45 countries and we are one of the medical faculties

that has the highest number of international students. There are two 1,000-bed

capacity hospitals that are affiliated with the Faculty of Medicine of the

University of Gaziantep. It is an institution where all kinds of surgical procedures

and diagnostic procedures are performed. Organ and bone marrow

transplantation are routinely done. With such academic work and publications,

our university is in the front lines of international rankings.

Welcome and wish you a successful meeting.

Prof. Dr. Y. Zeki ÇELEN

President of the 7th Annual Meeting of the MEACR

Dean of the Faculty of Medicine

The University of Gaziantep

Welcome Message from the MEACR

Executive Committee

Dear Colleagues and Friends, we meet once again at Gaziantep University that

has agreed so generously to host our meeting for the second time. And for

that, they have our deepest appreciation and gratitude. As a non-profit

scientific association that aims to build bridges in the Middle East to enhance

medical research and collaboration, we find our task burdened with political

complications in this area. Which made organizing the meeting this year

particularly challenging, but here we are. For more information about our

association please refer to our website: www.meacr.org.

We have so many people to thank for the realization of this event, mostly

Gaziantep University and its Rector, Prof. Ali Gür; the Faculty of Medicine of

Gaziantep University and its Dean, Prof. Yusuf Zeki Çelen and the dedicated

organizing committee, Mrs. Nur Incetahtaci, Dr. Ramazan Bal and Mrs. Amal

Kassab who have worked tirelessly and under a tight timetable to realize this

event. Of course, we also value the continuous support of Qatar University,

and its College of Medicine, particularly the VP and Dean of the College of

Medicine, Prof. Egon Toft.

On a final note, all the abstracts presented in this meeting can be published as

a full paper in the CCIJ: www.ccij-online.org. The CCIJ is preparing its 6th

Volume in 2018, and we like to invite you all to submit your next paper in its

upcoming issue, specially that with the support of the College of Medicine of

Qatar University, we are now able to provide once more a free and open access

journal for all researchers. We are grateful for all our reviewers and authors

who have already participated in the success of our past issues through their

participation and collaboration.

Thank you again for your support and participation in the 7th annual meeting of

the MEACR,

Ala-Eddin Al Mosutafa CEO of the Middle Eastern Association for Cancer Research

Editor in Chief of the Clinical Cancer Investigation Journal

Prof. College of Medicine, Qatar University

Associate member of the Biomedical Research Center of Qatar University

http://www.meacr.org/

http://www.ccij-online.org/

Organizing Committee

Honorary President: Prof. Dr. Ali Gür Gaziantep University, Gaziantep, Turkey Al Moustafa A-E MEACR & Qatar University, Doha, Qatar Kassab A Concordia University, Canada Çelen, Y.Z Gaziantep University, Gaziantep, Turkey Demirel C Gaziantep University, Gaziantep, Turkey Sucu M.M Gaziantep University, Gaziantep, Turkey Elmahli W Gaziantep University, Gaziantep, Turkey Bal R, Gaziantep University, Gaziantep, Turkey Taşdemir D Gaziantep University, Gaziantep, Turkey Zengin S Gaziantep University, Gaziantep, Turkey Elboğa U Gaziantep University, Gaziantep, Turkey

Scientific Committee

National

• Akil N, Turkey

• Bal R, Turkey

• Başkonuş İ, Turkey

• Bozdağ Z, Turkey

• Çelen Y.Z, Turkey

• Demirel C, Turkey

• Elboğa U, Turkey

• Erturhan S, Turkey

• Gokalp A, Turkey

• Gülşen M.T, Turkey

• Işık A.F, Turkey

• Sucu M. M, Turkey

International

• Aboussekhra A, SA

• Alachkar A, USA

• Alali F Q, Qatar

• Alaoui-Jamali M, Canada

• Alkhalaf M, Kuwait

• Al-Kuraya Kh, KSA

• Alsbeih G, SA

• Boudjelal M, KSA

• Chouaib S, France

• Dermime S, Qatar

• Desprez P-Y, USA

• Gali-Muhtasib H, Lebanon

• Gargouri R, Tunisia

• Khan H, USA

• Machaca Kh, Qatar

• Mraiche F, Qatar

• Pervez Sh, Pakistan

• Rabbani Sh,Canada

Day 1 : December 21, 2017 08:30 - 09:30 Registration

09:30 – 10:00 Official Opening

Keynote Speakers

Session Chairs: Dr. Hiba Bawadi & Dr. Ramazan Bal

10:00 – 10:30 Saghir Akhtar Doha, Qatar

EGFR signalling: From cancer to diabetes-induced vascular dysfunction

10:30-11 :00 Abbas Iqbal Lahore, Pakistan

New directions and advances in management of Hepatocellular cancer, Future with safety and hope

11:00 – 11:30 Coffee break- poster visit

11:30 - 12:30 Satellite Symposium: Nuclear Medicine

Session Chair: Dr. Hale Çolakoğlu Er & Dr. Elzem Şen

11:30-12:00 Sakıp Erturhan Gaziantep, Turkey

Therapeutic approach in Metastatic Prostate Cancer: Urological view-

12:00-12:30 Umut Elboga Gaziantep, Turkey

A new paradigm: Theranostic Applications in Metastatic Prostate Cancer

12:30 - 13:30 Lunch

Basic Research

Session Chairs: Dr. Saghir Akhtar & Dr. Abbas Iqbal

13:30 – 13:45 Abolfazl Movafagh Tehran, Iran

Breast Cancer Registry in Iran

13:45 – 14:00 Fatima Mraiche Doha, Qatar

Inhibition of p90 ribosomal s6 kinase potentiates cisplatin induced apoptosis, cell cycle arrest and anti-metastasis in human lung adenocarcinoma

14:00 – 14:15 Muhammad Safdar Lahore, Pakistan

Novel Relationship between 3'UTR region of EGFRs and miR-4533 genes with SNPs in Colorectal Cancer: In Silico and in Vivo

14:15 – 14:30 Ajaz Bhat Doha, Qatar

Curcumin regulates proliferation, autophagy, apoptosis and modulates intestinal barrier function in human colorectal cancer cells

14:30 – 14:45 Zehra Bozdağ Gaziantep, Turkey

The Evaluation of Satb2 Expression In Primary Epithelial And Metastatic Tumors Oh The Ovary

14:45 – 15:30 Coffee Break- poster visit

Translational Medicine

Session Chairs: Shamal Abdulah Al_Muffti & Dr. Fatima Mraiche

15:30 – 15:45 Wassim Almahli Gaziantep, Turkey

The Evaluation of Cd117 (C-Kit) Expression in Liposarcomas

15:45 – 16:00 Hiba Bawadi Doha, Qatar

Preventive and etiological role of nutrition in Oral and Pharyngeal Cancers

16:00 – 16:15 Hamid Yahya Husain Baghdad, Iraq

Top 10 cancers Incidence Rates, Pattern and Time Trends of among Iraqi Population for the last two Decades, Population and Hospital Based Registry

16:15 – 16:30 Basem Rajab Istanbul, Turkey

A Possible Prognostic Significance Of Tim1 Gene Variant In Laryngeal Cancer

16:30 – 16:45 Houda Drissi Casablanca, Morocco

Breast cancer and hormonal profile about 305 cases collected at the Mohamed IV center for the treatment of cancers in Casablanca

Day 2 : December 22, 2017

Clinical Research

Session Chairs: Dr. Abolfazl Movafagh & Dr. Moussa Alkhalaf

09:00 – 09:15 Zoubida Zaidi Setif, Algeria

Trends in cervical cancer survival in Arab World, 1990-2009

09:15 – 09:30 Omar Nimri Amman, Jordan

Bladder Cancer, 2005-2010 data. (Four MECC Countries, Jordan, Turkey, Israel and Cyprus)

09:30 – 09:45 Hadeel M. Fayyadh Fallujah, Iraq

Serological and molecular detection of humanherpes virus type 6 infection in Iraqi patients with acute and chronic lymphocytic leukemia

09:45 – 10:00 Fatima Ezzahra Imad Casablanca, Morocco

Colorectal Cancer In Patients Younger Than 40 Years: Experience Of The Mohamed Iv Center For The Treatment Of Cancer

10:00 – 10:15 Feras Alali Doha, Qatar

7-O-Methylpunctatin: A Homoisoflavonoid Scaffold with Antimetastatic Potential against MDA-MB-231 Breast Cancer Cells

10:15 – 10:45 Coffee Break- poster visit

Basic Research

Session Chairs: Dr.Zehra Bozdak & Dr. Hamid Yahya Husain

10:45 – 11:00 Moussa Alkhalaf Kuwait, Kuwait

How valuable is BRCA1 evaluation? Mutations pattern in Kuwaiti breast cancer patients

11:00 – 11:15 Mohamed Nizar Akil Gaziantep, Turkey

The role and clinical impact of genetic in breast cancer

11:15 – 11:30 Elif İşbilen Gaziantep, Turkey

Prognostic Roles of B-Cell Lymphoma 2 (Bcl-2) Expression in Breast Cancer

11:30 – 11:45 Ali Pamuk Gaziantep, Turkey

Expression And Purification Of Recombinant Active Tet Enzyme In E.Coli

11:45 – 12:00 Anas Azzam Ashour Doha, Qatar

Water-Pipe Smoking and Women’s Health: from pregnancy to breast cancer

12:00 - 13:30 Lunch

Clinical and Basic Research

Session Chairs: Dr. Ahmad Ibrahim & Dr. Waleed Arafat

13:30 – 13:45 Elzem Sen Gaziantep, Turkey

Four-Year Experience Of Pancreaticoduodenectomy At Gaziantep University Medical Faculty Hospital

13:45 – 14:00 Gulcin Elboga Gaziantep, Turkey

Anxiety, Depression in Carcinoma of Unknown Primary Patients Undergoing F-18 FDG PET-CT Imaging Procedure

14:00 – 14:15 Neslihan Bayramoğlu Tepe Gaziantep, Turkey

Determination of The Expression Levels Of Mirna 204-5p, Mirna 138-5p And Mirna 133-3p In Formaline Fixed Paraffine Embedded Tissue Samples Of Endometrial Cancer And

Relationship With The Prognosis

14:15 – 14:30 Yaman AlAhmad Doha, Qatar

Role of cell phone radiofrequency in head and neck cancer progression

14:30 – 14:45 Ala-Eddin Al Moustafa Doha, Qatar

Src/Abl tyrosine kinase inhibitor is a promising molecule for human papillomavirus-positive cervical cancer therapy

14:45 – 15:30

Coffee Break- poster visit

Basic Research

Session Chairs: Dr. Mir Faeq Ali Quadri & Dr. Ala-Eddin Al Moustafa

15:30 – 15:45 Waleed Arafat Alexandria, Egypt

A novel predictive marker of resistance to neoadjuvant Chemor adiotherapy in young Rectal Cancer patients

15:45 – 16:00 Havva Yeşil Çınkır Gaziantep, Turkey

The Role of GA-68 PSMA PET / CT in Evaluating Response to Docetaxel Therapy in Castration Resistant Prostate Cancer Patients

16:00 – 16:15 Ahmad H. Ibrahim Zakho, Iraq

Neuroprotective efficacy of Cocos nucifera Oil on Mammalian Cells after Serum Deprivation Chemotactic Grading Oxidative Stress in The Hypoxia and Ischemia

Ailments

16:15 – 16:30 Hale Çolakoğlu Er Gaziantep, Turkey

Efficacy of 64 detector computed tomography for the preoperative staging and resectability evaluation of pancreatic premalignant and malignant masses

16:30 – 16:45 Murat Karaoglan Gaziantep, Turkey

From hyperglycemia to hypoglycemia: A Case of Children with Nesidioblastosis

16:45 – 17:00 Shamal Abdulah Al_Muffti Duhok, Iraq

The Impact of Antiapoptotic and Angiogenesis activity of Fermented Virgin Coconut Oil (FVCO) as protecting Agent for neurodegeneration disease

THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP. TURKEY 1

ORAL PRESENTATIONS: DAY 1 21 December 2017: Gaziantep University, Turkey

Session Chairs: Dr. Hiba Bawadi and Dr. Ramazan Bal

10:00 – 10:30 Prof. Saghir Akhtar College of Medicine, Qatar University, Qatar

Saghir Akhtar is currently Professor of Pharmacology at the College of Medicine, Qatar University and Editor-in-Chief of the Journal of Drug Targeting. He was previously Professor and Director for the Centre for Genome-based Therapeutics, Cardiff University (UK) and more recently as Professor of Molecular Pharmacology at the Faculty of Medicine, Kuwait University.

Prof Akhtar holds a First class BSC (hons) degree in Pharmacy (Leicester School of Pharmacy, UK) and a PhD from the University of Bath (UK). After a post-doctoral fellowship at the University of North Carolina Medical School at Chapel Hill (USA), he began his independent academic career at Aston University (UK). He was also a visiting fellow at Oxford University (with Professor Ed Southern in the Department of Biochemistry) and later a Chairman of the Department of Pharmaceutics at Kuwait University. He has published extensively, and his multidisciplinary research has been internationally recognized by the award of several prestigious prizes including the CRS Young Investigator Research Achievement Award (USA), the Lilly Prize, the Pfizer Academic Award, (UK) and the British Pharmaceutical Conference Science Medal.

EGFR signalling: From cancer to diabetes-induced vascular

dysfunction

The four-membered EGFR/ErbB family of receptor tyrosine kinases, namely EGFR (also known as ErbB1), ErbB2, ErbB3 and ErbB4, are important signal relays for diverse pathways and regulate important functions such as cellular proliferation, motility, differentiation, invasiveness and apoptosis. Dysregulated signaling via EGFR/ErbB receptors is known to lead to the development of several cancers including malignant gliomas but there is now emerging evidence for their importance in other pathologies including diabetes-induced cardiovascular complications. In this presentation, I will review our own research on the development of targeted gene silencing strategies for inhibiting EGFR overexpression in glioblastomas and the role of ErbBs in mediating diabetes-induced vascular dysfunction. I will also present microarray-based gene expression profiling studies and proteomic data showing that overexpression and hyperphosphorylation of EGFR, and other ErbBs, in the diabetic vasculature are key early events leading to the development of diabetes-induced vascular complications. Blockade of ErbB signaling pathways with specific inhibitors prevented diabetes-induced vascular pathology in animal models of diabetes. Thus, these data suggest that strategies targeting the inhibition of EGFR/ErbB signaling that are already useful in cancer chemotherapy might also be useful for diabetes-induced vascular complications.


10:30 – 11:00 Dr. Abbas Iqbal Zainab Memorial Hospital, Lahore, Pakistan

New directions and advances in management of

Hepatocellular cancer, Future with safety and hope. Iqbal.A, Hassan.N, Batool.S, Abbas.Y, Kamel.E,

Hepatocellular carcinoma (HCC) is the leading cause of death in cirrhotic patients and the

third cause of cancer related deaths. Most HCCs are associated with well-known underlying

risk factors, in fact, HCC arise in cirrhotic patients in up to 90% of the cases, mainly due to

chronic viral hepatitis and alcohol abuse. Worldwide prevention strategies are put to avoid

the infection of new subjects and to minimize the risk of liver disease progression in infected

patients. HCC is a condition which lends itself to surveillance as at-risk individuals can readily

be identified. The American and European guidelines recommended implementation of

surveillance programs with ultrasound every six months in patient at-risk for developing

HCC. The diagnosis of HCC can be based on non-invasive criteria (only in cirrhotic patient) or

pathology. Accurately staging patients is essential to oncology practice. The ideal tumour

staging system in HCC needs to account for both tumor characteristics and liver function.

Treatment allocation is based on several factors: Liver function, size and number of tumors,

macro-vascular invasion or extra hepatic spread. The recommendations in terms of selection

for different treatment strategies must be made on evidence-based data. Resection, liver

transplant and interventional radiology treatment are mainstays of HCC therapy and achieve

the best outcomes in well-selected candidates. Chemoembolization is the most widely used

treatment for unresectable HCC or progression after curative treatment. Finally, in patients

with advanced HCC with preserved liver function, sorafenib is the only approved systemic

drug that has demonstrated a survival benefit and is the standard of care in this group of

patients. But after sorafenib failure so far no 2nd line systematic therapy is available till the

discovery of these novel molecules and the roads ends with darkness, but in medical science

after the each end it start new era of discoveries and we pleased to announce that at least

we able to discover and restore some further hope with safety and quality of life in form of

B.M molecules for these selected end stage patients.

Keywords: Hepatocellular carcinoma, Surveillance, Staging system, Radiofrequency ablation, Liver surgery, Liver

transplant, Transarterial chemoembolization, TKIs, B.M molecules.

Session Chairs: Dr. Hale Çolakoğlu Er & Dr. Elzem Şen

Therapeutic approach in Metastatic Prostate Cancer: Urological view Prof. Sakıp Erturhan: Gaziantep Univesrity, Turkey

A new paradigm: Theranostic Applications in Metastatic Prostate Cancer Prof. Umut Elboga: Gaziantep University, Turkey


Session Chairs: Dr. Saghir Akhtar & Dr. Abbas Iqbal

13:30 – 13:45 Prof. Abolfazl Movafagh Shahid Beheshti University, Tehran, Iran

Dr Abolfazl Movafagh PhD, is a distinguished professor and founder of the Department of Medical Genetics, in the School of Medicine, the second top University of Shahid Beheshti Medical University and Sciences, Tehran, Iran. He did his post doc in gene therapy at Tohoko University (2007-2008). His research interests reside in the field of leukemia and breast cancer. He is the lead investigator of several research projects for Msc and PhD students in the field of medical Genetics and cancers. He was presented with a distinguished professor award by the administration of Shahid Beheshti Medical University officials (2009). He was also awarded a national research fellow 3rd rank by Taberesy organization in Iran. He has more than 123 Pubmed or and ISI published papers and also 15 published Persian papers. He has translated/ written 15 international books in the field of medical genetics and cancers. He has delivered several oral presentations/guest lecturer in national and international conferences. He has teaching experience for medical, Msc, PhD student in the area of breast cancer, leukemia, medical genetics, syndrome, for more than 24 years. He is an editorial board member of 6 national and international journals. He was recently invited as guest leader editor for especial edition in the international Journal of Hindawi.

Breast Cancer Registry in Iran Movafagh Abolfazl1, M. Barez MR2, Maryam Hajiseyed Jadadi1 1 Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 2Cell and Molecular Biology Research Center, Department of Anatomy and Biology, Faculty of Medicine, Shahid Beheshti University, Tehran, Iran *Corresponding author: Department of Medical Genetics, Cancer Research Center, Shohada Referral Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. [email protected]

Cancer registry has an important role for research and the monitoring of cancer status in a country’s public health. The Second main cause of death in Iran is cancer. In ten malignancies of females in Iran during 2009-2010, breast cancer has stood at the top of the list. The first official registry of cancer in Iran was launched in Babol in 1976 after increasing reports about the prevalence of esophageal cancer. In 1984 the Parliament passed a bill mandating the report of all tissues "diagnosed or suspected as cancer tissue" to the Ministry of Health. According to the ICD-O-3 published in 2013, during ten years’ cancer registry found 52068 patients with breast cancer. 97.1% of these cases were female. Breast cancer was the first type of all cancers in Iranian females by 24.6%. Most of these cases were recorded as invasive tumors. The average annual crude incidence of primary breast cancer in females was 22.6 (95%CI 22.1–23.1) per 100,000 females which is lower than in low-middle-income neighboring countries. In Iran, breast cancer is amongst the five most common cancers and ranks first among cancers diagnosed in women. Studies from Iran suggest that breast cancer affects Iranian women at least one decade younger than women in developing countries, with the mean age ranging from 47.1 to 48.8 years. Until recently, Middle East and Asian countries had the lowest rates of breast cancer in the world, but the incidence has increased rapidly during the past two decades. Causes of the rapidly increasing incidence of breast cancer in Middle East and Asian countries are incompletely understood. With an estimated


1.4 to 1.6 million new cases diagnosed around the world in 2008, breast cancer is the most common cancer among women in high-and middle-income, but also in a growing number of low-income countries. According to the another study of breast cancer study of A. Sadjadi et al the age-standardized incidence rate (ASR) was 16.2 per 100 000 person/year. In contrast to more developed countries, the ASR of breast cancer was low, with the lowest rate seen in Ardabil province (Iran). The estimated mortality rate for cancer in Iran was 41.1 and 65 per 100 000 for females and males in 2004. The NCR data registry of breast cancer is not exact in monitoring the effect of screening programs or showing the current status of breast cancer in Iran. A quality breast cancer registry and a screening program for breast cancer are both needed.

Key Words: Breast Cancer, Incidence, Cancer Registry, Iran Cancer

13:45 – 14:00 Dr. Fatima Mraiche College of Pharmacy, Qatar University, Qatar

Dr. Mraiche received her BSc. in Pharmacology with distinction at the University of Alberta (Edmonton, Alberta, Canada). After completing her BSc in 2004, Dr. Mraiche pursued a PhD in Medical Sciences at the University of Alberta. She graduated in 2010, receiving numerous national and provincial scholarships, including the Canadian Institute of Health Research Frederick Banting and Charles Best Doctoral Scholarship, Heart and Stroke Foundation Doctoral Scholarship and the Alberta Heritage Foundation for Medical Research Doctoral Scholarship. Currently, Dr. Mraiche is an Associate Professor and the Chair of the Pharmaceutical Sciences Section at the College of Pharmacy, Qatar University.

Dr. Mraiche specializes in cardiovascular research and has extensive training in molecular biology, generation, maintenance and characterization of transgenic animals and adenoviruses, all highly specialized biomedical techniques. She has extended her research portfolio to identifying therapeutic targets for the treatment of lung adenocarcinomas with focus on the mitogen activated protein kinase cascade.

Dr. Mraiche has published seventeen peer-reviewed papers in international peer reviewed journals. She has also presented and published at international and national scientific conferences. Dr. Mraiche has received various competitive grants as principal investigator from the Qatar National Research Fund, including the major National Priorities Research Program (NPRP) fund.

Inhibition of p90 ribosomal s6 kinase potentiates cisplatin

induced apoptosis, cell cycle arrest and anti-metastasis in

human lung adenocarcinoma Nabeel Abdulrahman1, Siveen Kodappully Sivaraman2, Shahab Uddin2 and Fatima Mraiche1* 1College of Pharmacy, Qatar University, Doha, Qatar 2Translational Research Institute, Hamad Medical Corporation, Doha, Qatar

Background: World Health Organization reports that cancer is a leading cause of death worldwide, accounting for 8.8 million deaths in 2015, of which the major portion is due to lung cancer. Cisplatin has been widely used in the treatment of various types of cancers including lung carcinoma. However, drug resistance and cardio toxic side effects by cisplatin


are major concerns which limit their usage. To evade these limitations, cisplatin is co-administered with agents that enhance the sensitivity of cisplatin. Targeting signalling pathways that promote cell survival and proliferation of tumor cell would be highly recommended to inhibit progression of cancer. The mitogen activated protein kinase (MAPK) pathway including extracellular signal regulated kinase (ERK) and its downstream mediator, p90 ribosomal s6 kinase (RSK), is responsible for the regulation of various cellular events.

Methods: Our study examined the effect of BI-D1870 (RSK inhibitor) on cisplatin induced anti-metastasis, apoptosis and cell cycle arrest in A549 human lung adenocarcinoma cells. Cells were treated with cisplatin (32 μM) in the presence and absence of BI-D1870 (7.5 μM). To assess the anti-metastatic activity, cell migration assay was performed, where the ability of cells to migrate through a scratch wound drawn through a confluent cell culture plate was analyzed by measuring the scratch width. Western blotting was carried out to analyse the effect of treatment on the expression of various cell survival proteins (ERK and RSK), and those proteins involved in apoptosis (caspase 9, caspase 3, PARP). Flow cytometric cell cycle analysis was carried out by propidium iodide staining.

Results: The cell migration assay showed that the co-treatment of BI-D1870 with cisplatin inhibited the migration of cells across the scratch width when compared to cisplatin alone (74.2 ± 8.7 % cisplatin vs 16.6 ± 4.3 % cisplatin + BI-D1870, P = 0.0030). This suggested that BI-D1870 potentiated the anti-metastatic action of cisplatin. The combination treatment also resulted in increased expression of cleaved caspase 3, compared to cisplatin (84.6 ± 6.7 % cisplatin vs 142 ± 10 % cisplatin + BI-D1870, P = 0.0123). This indicated that BI-D1870 increases the apoptosis of cancer cells by increasing the sensitivity of cisplatin. The combination treatment also showed a non-significant increase in the cell number in S-phase when compared to cisplatin alone, suggesting a cell cycle arrest at S-phase.

Conclusion: Our results demonstrated that co-treatment of BI-D1870 along with cisplatin potentiated the anticancer activity of cisplatin in A549 lung cancer cells mainly through apoptosis and antimetastasis as shown by the increased cleaved caspase 3 expression and enhanced inhibition of cell migration respectively. These findings implicates that agents targeting RSK mediated cell survival pathway, has an applicability to be used as a combination drug along with cisplatin, as an adjuvant to chemotherapy against lung cancer.

14:00 – 14:15 Dr. Muhammad SAFDAR Department of biology, Virtual University of Pakistan, Pakistan

Dr. Muhammad SAFDAR is an Instructor (Biology) in the Department of Biology, Virtual University of Pakistan where he has been a faculty member and a student of doctorate since 2016.

Moreover, Muhammad is completed his M. Phil (Genetics and Bioengineering) at UVAS, Turkey. His Doctor of Veterinary Medicine (DVM) degree has been done in 2011 at UVAS, LAHORE, Pakistan. His research interests lie in the area of cancer genetics, polymorphisms, drug discovery, nanoparticles, especially cloning, transduction and protein estimation. He has collaborated actively with researchers in several other disciplines of medical and molecular biology, zoology, biostatistics, biotechnology, chemistry, particularly nanobiotechnology and use of nanoparticles in the treatment of breast cancer.


He has total more than 50 publications, more than 200 citations and about 65 impact factors. He is being supervision of undergraduate and post-graduate students. He is working on three different projects currently with a scientific team at Virtual University of Pakistan.

Novel Relationship between 3'UTR region of EGFRs and miR-

4533 genes with SNPs in Colorectal Cancer: In Silico and in

Vivo Muhammad Safdar*1, Yasmeen Junejo1, 2, Sana Zaheer1, H. Khawar Ali1, Sadaf Pervez1, M. Asad Akhtar3, Saima Mustafa1, M. Tariq Pervez2, Tanveer Hussain1, M.E.Baber1

1. Department of Biotechnology, Faculty of Science and Technology, Virtual University of Pakistan. 2. Department of Bioinformatics and Computational Biology, Virtual University of Pakistan. 3. Department of Medical Biology, Faculty of Health Sciences, University of Tromsø, Norway.

Animal Reproductive Biotechnology Institute, Guangxi University, China *Presenter email: [email protected]

Background: Epidermal growth factor receptors or EGFRs along with signaling pathways activated by these receptors have been found to involve in the development of colorectal cancers including its resistance to treatment with cytotoxic medicines. Anti-EGFRs, unresponsiveness to endocrine and poor prognosis has been found to be associated with colorectal cancer. EGFR is found to be involved in colorectal cancer and hence various clinical experiments are trying to test the role of anti-EGFR directed therapy. However, the rate of mutations in EGFRs is not well-defined.

Objective(s): The objective of this study was to specify miRSNPs on EGFRs and SNPs in miR-4533 genes targeting 3'UTR, and evaluate the effect of these with respect to apoptosis and cancer in colorectal by using computational analytical tools and qRT-PCR.

Methodology: We have done analysis using various computational tools such as microT-CDS, miRTarBase, miRcode etc. and we have got sequences from NCBI website and also with qRT-PCR.

Results and discussion: We detected 150 different miRNA binding sites (115 different miRNAs) and 51 different SNPs in binding sites of miRNA in 3'UTR of EGFRs gene. During this study we found that miR-4533’s binding site on EGFR has the SNP on EGFR 3'UTR and its genomic sequence has three SNPs association with the rs567034162 due to same binding site. Also, miR-6509-5p has two SNPs association with the rs920952718 due to same binding site. Here, miRSNP at EGFR 3'UTR and SNP miR-4533 genomic sequence cross-matches at the same site of binding region showed more effective results through qRT-PCR.

Interestingly, miR-4533’s binding site on EGFR has the SNP on EGFR 3'UTR and its genomic sequence has two SNPs association with the rs567034162 due to same binding site. Also, miR-6509-5p has three SNPs associated with the rs920952718 due to same binding site. Here, miRSNP at EGFR 3'UTR and SNP miR-4533 genomic sequence cross-matches at the same site of binding region displayed very effective outcomes via qRT-PCR. Besides, miR-4533 targets many cancer/apoptosis related genes such as RGPD8, COX15, SERPINA3, IL12RB2, OSTF1, MYOM2, PIAS2, HJURP, HOXA6, TCTN1, although it had no cancer/apoptosis related interaction proven before.

Conclusions: This means that miR-4533 may also have a critical effect on apoptosis via different pathways other than EGFRs. Hence, we may deduce that this is the first study

https://www.google.com.pk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0ahUKEwiD5oSyisDXAhXDtY8KHStSDmUQFggjMAA&url=http%3A%2F%2Fwww.redjournal.org%2Farticle%2FS0360-3016(15)02352-4%2Fabstract&usg=AOvVaw2THsziAgqR881l8aYhaZbp

https://en.uit.no/

mailto:[email protected]

http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169629.7











demonstrating an association between miR-4533 and cancer/apoptosis upon computational analysis in silico and in vivo. However, further studies are recommended to have better insight.

Keywords: EGFRs, 3′UTR region, miR-4533, SNPs, Computational analysis, qRT-PCR, HCT-116 cancer cells.

14:15 – 14:30 Dr. Ajaz Bhat

Sidra Medical & Research Center, Qatar

Dr. Bhat is currently working as a research scientist at Dept. of Translational Medicine, Sidra Medical and Research Center, Doha, Qatar. He completed his Ph.D. from one of the premier institutes (All India Institute of Medical Sciences, AIIMS) in India. After his Ph.D., he moved to Vanderbilt University Medical School, Nashville, TN, USA for postdoctoral fellowship. During his eight years of postdoctoral training at Vanderbilt, he has gained wide experience in the field of cancer biology. His focus of research was on the role and regulation of tight junction proteins (Claudins) in colorectal cancer and the role of bile acid induced APE1/Ref1 in esophageal adenocarcinoma. He has published in well reputed journals like GUT, Oncogene, Cancer Research, Molecular Cancer and many more enlisted in his CV. He has attended many international meetings, conferences, symposia to present his research results. He has been also awarded from Immunology society and American Association of Cancer research. He is an active member of many immunological and cancer societies. He is also serving in the review committee of many journals.

Curcumin regulates proliferation, autophagy, apoptosis and

modulates intestinal barrier function in human colorectal

cancer cells Ajaz Bhat1, Jayaprakash Babu2, Roopesh Krishnakutty3, Sheema Hashem1, Santosh K. Yadav1, Shahab Uddin3, Punita Dhawan2, Mohammad Haris1 1 Division of Translational medicine, Sidra Medical and Research Center, Qatar, 2University of Nebraska medical center, Omaha, NE-68198, 3 Translational Research Institute, Hamad Medical Corporation, Qatar

Background: Colorectal cancer (CRC) is the third most common cancer in Qatar and a major health concern for the Qatari population. According to the National Cancer Strategy Qatar, rates of CRC incidences are expected to increase despite significant advances are made in the screening/diagnosis of the disease. Furthermore, it is the tumor progression especially metastasis to distant organs that causes the CRC-patients to die. Thus, dire need for alternative therapies with the potential to inhibit key signaling pathways that regulate CRC-progression/metastasis is crucial. Epidemiological data suggest that dietary manipulations play an important role in the prevention of many human cancers. Curcumin, the yellow pigment in turmeric has been widely used for centuries in the Asian countries without any toxic effects. Curcumin is a naturally occurring powerful anti-inflammatory medicine. The anticancer properties of curcumin have been shown in cultured cells and animal studies. Curcumin has promising potential in cancer prevention and therapy by interacting with proteins and modifying their expression and activity, which includes transcription factors, inflammatory cytokines, and factors of cell survival, proliferation, and angiogenesis. In this


study, we investigated the effect of curcumin on proliferation, autophagy, apoptosis and tight junction proteins.

Methodology: SW480, HT29 and HCT116 cells were exposed to curcumin (0, 10, 20 and 50uM) for 24hrs. The protein expression levels of apoptotic, autophagy markers and tight junction proteins were evaluated by immunoblotting. The CellTiter 96 Aqueous One Solution Cell Proliferation Assay was used for determining the number of viable cells. Colony forming and wound healing assay were used to examine the curcumin effect on tumorigenic and/or invasive abilities of the cell lines. STAT3 transcription activity was studied by luciferase reporter assay. Immunofluorescence assay was used to examine the localization of tight junction proteins after exposure to curcumin.

Results: Exposure of SW480, HT29 and HCT116 cells to curcumin led to decrease in cell proliferation and increased apoptosis in a dose- and time- dependent manner. Assays using growth in soft-agar and wound healing further confirmed ability of curcumin to decrease tumorigenicity. Tight junction proteins (claudin-1 and claudin-7) were found to be altered in expression and localization pattern. Moreover, treatment with curcumin induced autophagy in a dose- and time- dependent manner. Finally, treatment with curcumin increased the expression levels of p-JNK however, treatment with autophagy inhibitor alone or in combination with curcumin prevented the upregulation of p-JNK.

Conclusion: Taken together, outcome from our study suggests that the curcumin treatment of human colorectal cancer cells induces apoptosis and autophagy mediated by JNK pathway. Further studies are underway to delineate the signaling axis by which curcumin mediates alteration in tight junction proteins accompanied by repair in intestinal barrier function.

14:30 – 14:45 Dr. Zehra Bozdağ

Pathology Department, Gaziantep University

I graduated from Erciyes University, faculty of medicine and studied as an resident in the pathology department in Inonu University. I am studying as an Assistant Prof in Gaziantep University, Pathology Department from 2012 till now

.

THE EVALUATİON of SATB2 EXPRESSİON in

PRIMARY EPITHELIAL and METASTATIC

TUMORS oh the OVARY

Esra OZ, Zehra BOZDAG Gaziantep University, Pathology Department, Gaziantep, TURKEY

Ovarian cancer is the second most common gynecologic cancer in women and the seventh most common cause of cancer death in worldwide. Differential diagnosis between primary and metastatic neoplasm can be problematic in some cases.

The special AT-rich sequence-binding protein 2 (SATB2) is a nuclear matrix- associated protein that is important for growth and development. SATB2 was shown to be a sensitive and highly specific marker for colorectal carcinomas (CRCs). Based on this, it recommended a useful immunohistochemical marker for metastatic ovarian tumor of colorectal origin.


SATB2 expression also reported in lung, breast, pancreas, renal, laryngeal, esophageal carcinomas and bone cancers.

In this study we aimed to evaluate SATB2 expression in primary epithelial and metastatic ovarian tumors, and determine its significance between subtypes.

The samples included in this study were obtained from the archives of Pathology Department, at Gaziantep University from 2004 to 2017. The study group consisted of 148 cases of primary epithelial tumor and 29 cases of metastatic ovary tumor.

54.5% of mucinous carcinomas, 51.7% of endometrioid carcinomas, 18.2% of high grade serous carcinomas, 17.9 of borderline mucinous tumors, 6.7% of borderline serous tumors and 51.7% of metastatic ovarian tumors showed SATB2 immunopositivity. SATB2 expression showed no specificity for all the subgroups.

Metastatic ovarian tumors consisted of colon, breast, upper gastrointestinal system and appendix also showed SATB2 expression in different rates. All the colorectal carcinomas showed SATB2 positivity compatible with the literature.

To best of our knowledge, our study is the first study that shows SATB2 expression in primary ovarian tumors in addition to metastatic ovarian carcinomas. We determined SATB2 in all groups of primary and metastatic ovarian tumors. Further studies including larger scales are warranted to show SATB2 specificity for the subtypes.

Keywords: metastatic, ovary tumor, primary, SATB2

Session Chairs: Dr. Shamal Al Muffti & Dr. Fatima Mraiche

15:30 – 15:45 Dr. Wassim Almahli Faculty of Medicine, Gaziantep University, Gaziantep, Turkey

Dr. Wassim ALMAHLI was born in Damascus /Syria in 1977 where he received his secondary education. He graduated from the Faculty of Medicine of Aleppo University in 2001, and got his general surgery specialty from Aleppo university hospital in 2009. His thesis concentrated on the surgical management of hepatic traumas. Dr. Wassim worked in private hospitals in Aleppo until 2010. He began his fellowship in the general surgery department at Gaziantep University hospital / Turkey and increased his practical experiences especially in the field of the cancer surgery. After finishing his fellowship; he became an assistant professor of the general surgery and a member of the academic staff in the English section of the medicine faculty of Gaziantep in 2013. During his academic practice he produced numerous scientific publications and conference presentations.

The Evaluation of Cd117 (C-Kit) Expression in Liposarcomas

Wassim ALMAHLI1, Zehra BOZDAG 2, Ersin BORAZAN1, M. Avni GOKALP1 Omer Faruk DIZIBUYUK2, Metin KARAKOK2 1 Gaziantep University, Department of General Surgery, Gaziantep, Turkey 2 Gaziantep University, Department of Pathology, Gaziantep, Turkey


Introduction: Liposarcoma (LS) is the most common soft tissue sarcomas in adults. They importance of these tumors based on their high risk of local recurrences and distant metastases.CD117(c-Kit) is a type III receptor tyrosine kinase (RTK) that acts as a receptor for mast cell growth factor(also known as stem cell factor or kit ligand) , plays a crucial role in cancer occurrence as an oncogene.

In this study we aimed to investigate the expression of CD117 (c-Kit) in liposarcoma, and to detect the importance of this expression in the differential diagnosis of subtypes for the diagnosis and treatment.

Materials and Methods: The materials included in this study were obtained from the archives of the Department of Pathology, Gaziantep University. The study group consisted of 43 cases of LSs. One representative tissue block from each case was selected and immunohistochemical antibody of CD117 was studied using an automated immunohistochemistry-staining device the cases were considered to be positive when >1% tumor cells showed cytoplasmic CD117 expression with any intensity.

Results: Nine (20.9%) of - (6 myxoid, 2 pleomorphic, 1 well differentiated LS) - 43 LS cases showed CD 117 expression. The expression was focal in all cases.

Discussion: There have been several reports of CD117 expression in limited soft tissue tumors. Hornick and Fletcher performed immunohistochemical analysis for CD117 in 365 soft tissue sarcomas. They found no CD117 expression in LSs. Our study showed focal positivity in different subgroups. Depending on the positive CD117 expression results. Tyrosine kinase inhibitors (TKI) can be placed in the treatment of tumors such as gastrointestinal stromal tumors.

Conclusion: Further studies with large number of cases are warranted to evaluate the CD117 expression in liposarcoma and the effect of possible use of TKIs for the treatment.

Key Words: CD117, C-Kit, Liposarcoma

15:45 – 16:00 Dr. Hiba Bawadi Biomedical Research Center,

Qatar University, Qatar

Dr. Bawadi is a professor in Nutrition and an expert in nutritional epidemiology of non-communicable diseases. Dr. Bawadi published 50+ refereed papers, presented 29 papers in international meetings, and held 17 workshops on clinical nutrition of diabetes and obesity for professional nutritionists.

Dr. Bawadi is currently the Chair of the Continuous Professional Development of Health Practitioners of the health cluster at Qatar University. She is also associated with the Department of Biomedical Sciences of Qatar University.

Preventive and etiological role of nutrition in Oral and

Pharyngeal Cancers Hiba Bawadi and “Mo’ez Al-Islam” Faris

Oral and pharyngeal cancers (OPC) are ranked as the as the sixth most common neoplasms. Dietary factors linked to increased risk of OPC include increased consumption of red meats


and saturated fats. On the other hand, some dietary factors were linked to reduced risk od OPC such as consuming enough fruits and vegetables, legumes, unsaturated fats and dietary intake of bioactive phytochemicals. The molecular mechanisms of action by which dietary factors may influence risk of OPC are not fully elucidated. However, the antioxidation power of dietary antioxidants maintains cell membrane integrity and protects DNA from damage. Other chemopreventive mechanistic actions of dietary factors include the modulation of cell signaling pathways associated with cells proliferation, migration and apoptosis.

16:00 – 16:15 Prof. Hamid Yahya Husain

University of Baghdad, Baghdad, Iraq

WHO, CDC, and Uniceif expert and EMPHNET consultant, poliomyelitis global Eradication, Outbreak response team, global health and immunization. WHO consultant Outbreak alert and response team n Nominated to Emro Regional Counselor of International epidemiological association, Global Health Mentor at Swedish global health mentorship network, Expert consultant Public Health and Epidemiology at Eastern Mediterranean Public Health Network ( EMPHNET)

Professor at Dubai residency training program/ Community and family medicine/ Arab Board for health specializations. Professor of Community Medicine and Public Health Medicine at Faculty of Medicine, University of Baghdad. He also worked as environmental expert ant ministry of environment, Iraq, Worked as training consultant, researcher, and programs manager at ministries of health and higher education and scientific research in different Middle East and North Africa region. Member of editorial Board of Middle east journal of internal medicine, Middle east journal of age and aging, middle east journal of Alzheimer and psychiatry

Dr. Husain is a member of different international, regional and national associations e.g. APHA, IEA, MENAPF, EMAME, American college of occupational and environmental medicine, American college of Epidemiology, American academy of family medicine, Canadian College of family physician,

Supervised more than (30) PhD thesis, 25 MSc thesis, achieved about 150 research work. And contribute to CDC textbook on Ethics in Public Health, cases spanning around the Globe. Editorial Board and Peer Reviewer at many international medical and health Journals

Top 10 cancers Incidence Rates, Pattern and Time Trends of

among Iraqi Population for the last two Decades, Population

and Hospital Based Registry Hamid Yahya Husain1, Sharif F. A. Al-Alawachi2 1Faculty of Medicine, University of Baghdad, Baghdad, Iraq 2Merjan Teaching Hospital Oncology Cancer Center, Babylon Health Directorate, Babylon, Babylonia Email: [email protected]

Background: Global cancer rates have been increasing primarily due to many reasons: an aging population and lifestyle changes in the developing world were major causes. In 2008, approximately 12.7 million cancers were diagnosed, and 7.6 million people died of cancer worldwide.



Objectives: To study the epidemiological patterns of the top 10 registered cancers over the years of 1991-2008 in Iraq. To identify the socio-demographic characteristics and determinants of cancers in Iraq and to identify time trends.

Results: The study revealed that the number of cancer cases registered was 5720 in Iraq (31.05) per 100,000 in 1991 to 14,180 (44.46) per 100,000 population in 2008. While age incidence of cancer in Iraq increased with age, starting from almost 7 cases per 100,000 population at age below 10 years to 398 cases per 100,000 population at age 70 years old, the top 10 cancer incidence in Iraq was breast cancer followed by lung cancer, leukemia, bladder cancer, brain and CNS, non-Hodgkin’s lymphoma, colorectal cancer, stomach cancer, skin cancer excluding melanoma, larynx cancer. Cancer incidence rate significantly increases after 2000 (mean incidence was around 55 cases per 100,000 population) in comparison with the period before 2000 (mean incidence was 40 cases per 100,000 population). The highest age incidence rate is the age of 70 years of (397 per 100,000) followed by 65+ years (327 cases per 100,000 population).

Conclusion: Cancer incidence in Iraq is relatively high and trends are up going in terms of quantity and variables related like age sex etc. The figures reflect little increment due to population growth. Prevention and management of cancer are still inadequate. Recommendations: Strengthening the national cancer prevention, cancer therapeutic and cancer registry program to improve cancer related outcomes; addressing effective interventional strategies in terms of risk management, life style promotion and hazardous exposure through establishing national health related multi-stakeholders projects.

Keywords Incidence Rate; Pattern; Cancer; Iraq

16:15 – 16:30 Prof. Basem Rajab

Istanbul University, Istanbul, Turkey

Dr. Rajab graduated from the University of Sebha-Faculty of Engineering and Technology in 1995. He then worked as a Medical Lab Technician at the University of Tripoli, Faculty of Medical Technology until 2002 afterwards he joined the Abo-Salem Trauma Hospital. Dr. Rajab obtained his MSc. In Biological science from the University of Al-Bayte, Department of Biological science, Al-Mafraq.

Dr. Rajab worked at the University of Tripoli, Faculty of Medical Technology, Medical High institute of Garapoli, Mselata, and then in Abo-Salem, Medical Lab Department until 2012, afterwards he became a staff member at the University of Tripoli, Faculty of Medical Technology, Pathology Department. In 2014 Dr. Rajab joined the University of Kastamonu, Institute of Sciences, Department of Genetics and Bioengineering, Kastamonu, Turkey; where he obtained his PhD. In Immune pathology, Area of research (Evaluating of Homocysteine Variations in Turkish Patients with Correlated Cancer). And in 2017 he joined the Molecular Medicine Department, Aziz Sancar Institute of Experimental Medicine at Istanbul University


A POSSIBLE PROGNOSTIC SIGNIFICANCE OF TIM1 GENE VARIANT

IN LARYNGEAL CANCER Şeyda Ercan1, Dilara Sönmez1,Basem Rajab2,Ayşegül Verim3,Mehmet Tolgahan Hakan1,Bayram Kıran2, İlhan Yaylım1 1Molecular Medicine Department, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey. 2Genetic and Bioengineering Department, Faculty of Science, Kastamonu University, Kastamonu, Turkey. 3Department of Otorhinolaryngology/Head and Neck Surgery, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey.

Objectives: T-cell immunoglobulin and mucin domain 1 (TIM-1) is a protein that in humans is encoded by the HAVCR1 gene. TIM-1, is a member of the TIM gene family, it is preferentially expressed on Th2 cells and has been identified as a stimulatory molecule for T-cell activation. The relationship between the immune response-related genes and cancer has been demonstrated in a number of studies. This study aimed to investigate possible relationships of TIM-1 gene variant in laryngeal cancer (LC).

Materials-Methods: TIM-1 (416G>C) polymorphism was investigated in 219 subjects (77 subjects with LC and 142 healthy individuals as controls) by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).

Results: According to our data, it has been found an increased frequency of CC genotype in laryngeal cancer patients but this difference was not statistically significant (p>0,05). The patients who have distance metastasis (%62,5) have increased GC genotypes than those with no distance metastasis (%37,8) and this value was statistically significance (OR:1,652, CI:1,203- 2,267, p= 0,05 ). Moreover; the patients who have node metastasis have increased frequency of G allele (%72,9) than those with absence node metastasis (%54,2) (OR: 1,346, 95% CI: 0,994-1,822).

Conclusion: According to our research, TIM-1 (416G>C) polymorphism is associated with the progression but not on the risk of laryngeal cancer in Turkish population, which is the first data for the contribution of the human TIM-1 gene in laryngeal cancer. Our findings regarding the association of TIM-1 (416G>C) polymorphism and clinicopathological characteristics should be considered in the further studies with larger sample sizes to assess the impact of TIM-1 gene on disease.

Keywords: TIM-1 (416G>C) , polymorphism, laryngeal cancer.

16:30 – 16:45 Mrs. Houda Drissi

University Hassan II of Casablanca, Morocco

DRISSI HOUDA is a PhD student in cancer biology; she carries out her research work at the Mohamed VI center for cancer treatment in Casablanca in collaboration with the faculty of sciences Ben M'sik Hassan II University of Casablanca. She is currently working on a project that focuses on breast cancer, a clinical and biological epidemiological study on hormonal and nutritional risk factors for breast cancer in the Moroccan population.

Today she will present a relevant study entitled: "Breast cancer and hormonal profile about 305 cases collected at the center Mohamed IV for the treatment of cancers in Casablanca."

https://www.wikizero.com/en/Protein

https://www.wikizero.com/en/Gene

https://www.wikizero.com/en/Th2_cell

https://www.wikizero.com/en/T-cell


Breast cancer and hormonal profil about 305 cases collected

at the Mohamed IV center for the treatment of cancers in

Casablanca

DRISSI Houda1. IMAD Fatima Ezzahra1, BENDAHHOU Karima2.. BENIDER Abdelatif 3. RADALLAH Driss1 1: Faculty of Sciences Ben M'Sik Hassan II University of Casablanca Morocco. 2: Cancer registry of the Greater Casablanca Morocco region. 3: Mohammed VI Center for the Treatment of Cancers, Casablanca Morocco.

Breast cancer is the leading woman in terms of incidence and mortality in the world. The objective of our study is the determination of the risk factors, in particular the hormonal factors on the appearance of this pathology.

Our study included 305 newly diagnosed breast cancer patients at the Mohamed IV center for the treatment of Casablanca. Data collection is done using a standardized questionnaire, administered face-to-face to patients and completed from patient records. The statistical analysis of the epidemiological data was done using the R software.

Our study population had a mean age of 50 years with a standard deviation of 11.35; more than half of the patients are married. Most are housewives who live in urban areas.

In our study population parity is on average 3 with a standard deviation of 2.62 and extremes ranging from 0 to 11 children. The average age at first pregnancy of our patients was 23.66 years with a standard deviation of 5.97 and extremes ranging from 11 to 40 years. 96.41% of patients breastfed their children with an average breastfeeding duration of 50.47 months.

56.1% of the patients were menopausal, the average age at puberty was 13.31 years and the average age of onset of menopause was 49.86 years.

The medical history of the study population shows that only 2% of patients had used mammary mastosis treatment, 3.3% of hormone replacement therapy, 6.2% of patients were treated with ovulation inducing agents, 7.2% were treated for irregular cycle and finally 60% of patients used oral contraceptive with an average duration of 8.43 years with a standard deviation of 6.54.

Invasive ductal carcinoma was the most common histologic type in our patients (77.7%) with SBR II grade in 68.3% of patients. Hormonal receptors were overexpressed in 83.26% of cases, 29.9% of patients had HER2 positive and triple negative only accounted for 13.22% of patients.

To deepen our knowledge of the subject of breast cancer, its risk factors and its management in Moroccan women, other etiological studies are recommended to answer these questions.

Keywords: breast cancer, prospective study, hormonal profile.


ORAL PRESENTATIONS: DAY 2 22 December 2017: Gaziantep University, Turkey

Session Chairs: Dr. Abolfazl Movafagh & Dr. Moussa Alkhalaf

9:00 – 9:15 Prof. Zoubida Zaidi University of Setif. Algeria

Dr. Zoubida Zaidi Associate professor on epidemiology from the University of Setif, Algeria and chief of the cancer registry Unit, Setif, Algeria

Trends in cervical cancer survival in Arab

World, 1990-2009 Introduction: Cancer survival is a key measure of the effectiveness of health-care systems. Globally, cervical cancers (CC) represent 530,000 new cases per year and account for the vast majority of all HPV-attributable cancer cases worldwide. Nearly half of the cases are diagnosed in women <50 years old, and more than two-thirds are diagnosed in less developed countries. Cancer is responsible for a substantial proportion of disease burden in the Eastern Mediterranean Region (EMR), Between 2005 and 2015, incident cases increased by 46%, deaths by 33%, Cancer caused 722,000 cases, 379,000 deaths. In females, breast cancer, leukemia, and cervical cancer were the most common incident cancers with 177.4 thousand, 20.8 thousand, and 19.6 thousand cases, respectively

Objective: To describe the trends of the survival of CC patients diagnosed in Arab countries.

Material and Methods: This report is a summary of the two survival figures of CONCORD study 1 (1990-1994) and CONCORD study 2 (1995-2009). Individual cervical cancer tumour records were submitted by 06 population-based cancer registries in Arab countries (Jordan, Saudi Arabia, Qatar, Algeria, Libya and Tunisia) for patients (15-99 years) diagnosed during 1990-2009 and followed up to 31 December 2009. Estimated five-year net survival, adjusted for background mortality by single year of age, sex, calendar year in each country.

Results: Worldwide, data for cervical cancer are available for 602 225 women, 192 registries in 51 countries provided data for 1995–99, 244 registries in 58 countries contributed data for 2000–04, and 244 registries in 61 countries provided data for 2005–09. The global range in 5-year net survival from CC is very wide, particularly in Africa, Central and South America, and Asia. For patients diagnosed during the period 2005-2009, the age-standardized five-years net survivals were respectively higher 70% in Qatar but is based on only 16 cases and the lowest rate between 1995-1999 and 2005-2009 cervical cancer survival was 50% or higher in all other countries, except for Libya (Benghazi, 39%),

Conclusions: Comparison of population-based cancer survival CONCORD study showed very wide variations in survival from cervical cancer in Arab world. Cancer survival research is being used to formulate cancer control and the need to implement effective strategies of primary prevention.


09:15 – 09:30 Dr. Omar Fayez Nimri Cancer Prevention and Control Department, Jordan

Dr Nimri is the head of the cancer prevention and control management, he is also

the director of the Jordan National Cancer Registry. Dr. Nimri obtained his bachelors

degree in 1990 from Pakistan as a surgeon, and went on to obtain several diplomas,

including: Korean Acupuncture from Sri-Lanka in 1991, community medicine from

Jordan in 2002, Cancer Prevention and Control Diploma from the USA in 2006,

Cancer registration and CanReg software from IARC France in 2005/2007 and

Cancer prevention and Etiology Diploma from the UM School of Public Health,

University of Michigan, USA 2008.

Dr. Nimri has many achievements in the field of cancer on local, regional as well as international levels, particularly concerning issues pertaining to cancer burden epidemiology, prevention, screening and registration.

Bladder Cancer, 2005-2010 data. (Four MECC Countries, Jordan,

Turkey, Israel and Cyprus) *** MECC -Middle East Cancer Consortium

Background: Cancer registration is the fundamental backbone of national cancer control plans worldwide, this study compares the cancer data of selected cancer from four of the MECC countries, Bladder cancer in this paper. The analysis involves both the In-situ and invasive bladder cancer.

Much of the variation in bladder cancer incidence internationally may partly be due to different registration practices for low-grade, or non-invasive, of the bladder Ca.

Method: The analysis involves both the In-situ and invasive bladder cancer. Not all risk factors or variables of Bladder Cancer are collected; in the four registries, which restrain full comparison... Age-standardized incidence rates (ASR) calculated with WHO world standard population (2000-2025). Annual percent changes (APC) calculated too.

Result: Males: females Bladder Cancer Ratio in Jordan was 7:1. Age Standard Rates (ASR) were highest among the Israeli-Jewish and lowest rates noted among the Jordanian’s population, Overall ASR (Male, Female per 100,000) Jordanians 7.4 (M:12.8/F:1.9) Israeli-Jewish 17.6(M:31.6/F:6.3).

Age specific incidence rate (ASIR) of bladder cancer increased with the increasing of age especially in males mostly above the age of 70 years, highest Israeli-Jewish (299.17**) Turkish (280.5) Cypriots (274.6) Israeli-Arab (262.4) and Jordanians (89) compared with SEER (351.2).

Data showed that most of the cases were invasive type ranging from (99.3%) among Turkish cases and the lowest was among the cases from Cyprus (77.5%) while the (in-situ) cases highest were among the Cyprus data followed by the Israeli population and the lowest among the Turkish.

Recommendation: Increasing public awareness of bladder cancer and the risk factor may lead or be an attribute to its existence. Prevention should be emphasis with high commitment, avoidance strategies in which person should avoid exposure to any of the risk factors (smoking, certain food, exposure to radiation…) or other agents and try to keep it to the minimum levels.


09:30 – 09:45 Hadeel M. Fayyadh University of Fallujah, Collage of Veterinary Medicine

Fallujah, Iraq

Dr. Fayyadh graduated from the College of Veterinary Medicine- Baghdad University with B.V.M.S. in 2001. Then she completed her M.Sc. study in Medical Microbiology at the College of Medicine- Al-Anbar University in 2007 where she specialized in Medical Microbiology- Virology. Soon after that and since 2008 she worked in College of Veterinary Medicine at Fallujah University as a lecturer at the Department of Microbiology. During that time she obtained her PhD in Medical Microbiology-Virology with a scholarship at the College of Medicine- Al-Mustansiriyah at 2015, then she went back to teaching at the same university. During her carrier, she taught different scientific subjects including Biology science, Immunology, and Virology. Her interests are in the field of viral diseases where she conducted more than 7 scientific projects on this issue, and her findings were published in local and international journals. She also presented her work at various local conferences in Iraq.

Serological and molecular detection of humanherpes virus

type 6 infection in Iraqi patients with acute and chronic

lymphocytic leukemia

Background: Human herpesvirus type 6 (HHV-6) is associated with roseola infantum during childhood followed by life-long latency that periodically reactivated in immuneocompromised individuals causing serious consequences. In spite of several studies to establish the pathogenic role of HHV-6 in lymphoid malignancies, the issue is still controversial.

Objectives: The present study was arranged to explore the association of HHV-6 infection among Iraqi patients with acute and chronic lymphocytic leukemia using different serological and molecular techniques.

Patients and methods: This cross-sectional case control study was conducted in National Center for Hematological Diseases (NCHD) at Al-Mustansyria University and Baghdad Teaching Hospital (BTH) in Baghdad-Iraq from September 2013 till November 2014. A total of 29 patients consists of 24 patients with acute lymphocytic leukemia and 5 patients with chronic lymphocytic leukemia of both sexes, the age range was 14-80 years. The diagnosis of lymphomas was based on hematological and histopathological criteria. 59 apparently healthy individuals from unpaid blood donors were enrolled as control group. The age range was 14-59 years. Human privacy was respected by taken participant's oral consensus. The anti- HHV6 IgG antibody was detected for all patients and control by two different methods using ELISA and IFAT, while the anti- HHV6 IgM antibody was detected by ELISA. Real -Time PCR was done for quantification of the HHV6 A-B genome. Statistical analysis was done using the Statistical Package of Social Science (IBM-SPSS), Version 23, and P values less than 0.05 were considered significant.

Results: The anti-HHV6 IgG was positive in (70.8%) of the patients with ALL and (61.0%) of the controls by IFAT technique. Likewise, the ELISA results showed insignificantly higher positivity rate among patients compared to healthy individuals (87.5% Vs 72.9, p =0.151). on the other hand, all the 5 patients (100%) with the CLL were positive for anti-HHV6 IgG by


IFAT, versus (61.0%) of controls were positive. Again using the ELISA technique, the anti-HHV6 IgG positivity rate among CLL patients was 80%, while that of control group was 72.9%. However, the difference was statistically insignificant (p=0.729). Regarding the PCR results, the HHV-6 DNA was detected in only one patient with ALL (4.2%), while the viral DNA was not detected in any of the controls. Similarly, the viral DNA was not detected by PCR among CLL patients.

Conclusion: Although a higher anti-HHV-6 antibodies positivity rate among patients with ALL and CLL, the pathogenic role of the virus in the development of these malignancies was difficult to be ascertain.

Keywords: Human herpesvirus-6, anti-HHV-6 antibodies, ALL, CLL.

9:45 – 10:00 Ms. Fatima Ezzahra Imad University Hassan II of Casablanca, Morocco

Imad Fatima ezzahra is a PhD student in cancer biology; she carries out her research work at the center Mohamed VI for the treatment of cancer in Casablanca in collaboration with the faculty of sciences Ben M'sik Hassan II University of Casablanca. She is involved in a project on colorectal cancer, a clinical and biological epidemiological study and nutritional risk factors for colorectal cancer in a Moroccan population.

Today she will present us a relevant study entitled: "Colorectal cancer in patients younger than 40 years: experience of the Mohamed IV center for the treatment of cancer."

COLORECTAL CANCER IN PATIENTS YOUNGER THAN 40 YEARS:

EXPERIENCE OF THE MOHAMED IV CENTER FOR THE TREATMENT OF

CANCER 18Fatima Ezzahra IMAD, 1Houda DRISSI, 2Sofia Majdoul, 2Nezha TAWFIQ, 3Karima BENDAHHOU, 4Nadia TAHIRI JOUTI, 2Abdellatif Benider, 1Driss RADALLAH. 1: Faculté des Sciences Ben M'Scik Université Hassan II de Casablanca, Maroc. 2 : Centre Mohamed VI pour le traitement des cancers, CHU Ibn Rochd , Faculté de médecine et de pharmacie, Université Hassan II, Casablanca, Maroc. 3 : Registre des cancers de la région du grand Casablanca, Maroc. 4 : Faculté de médecine et de pharmacie, Université Hassan II, Casablanca, Maroc

Colorectal cancer is the most common form of digestive cancer in the world. This location is rare in patients under 40 years old. Actually, it’s known to have a poor prognosis. The objective of this work is to study the epidemiological, clinical, pathological and therapeutic profile of this cancer in young people compared to the elderly taken in charge at the Mohammed VI Center for cancers treatment during the years 2014-2015.

This is a cross-sectional study, including cases of colorectal cancer in the Center. Data collection was based on patient records and analyzed by R software.

During the study period, 330 patients were included and divided into two groups: G1 <40 years and G2> 40 years.


15% of patients were less than 40 years old. There is a slight male predominance, with a sex ratio of 1.04. The presence of a history of CRC in first-degree relatives was noted in 11 patients in the G1 group (22.45%), and in the G2 group (8.89%), p = 0.03.

The rectum tumor was found in 40.8% for the G1 vs 51.6% for the G2. In addition, sigmoid colon cancer was the most frequent tumor site of colonic cancers in both groups.

The adenocarcinoma Lieberkühn accounted for 83% of all tumors in the elderly vs. 69.39% in the young (p = 0.01). Mucinous carcinomas were more frequent in young patients (24,49% vs. 13,16 %; p=0,01).

In our study, protocols of cancer treatment colic were in 83 % of elderly people and 50 % young people by the association surgery and chemotherapy. Exclusive surgery was practiced in 16 % young people and 4 % of eldery (p=0,001), and the palliative chemotherapy in 33 % young people vs 16 % of eldery.

For the rectal cancers, treatment was principally a preoperative radiotherapy associated to the surgical treatment in 66 % young people and 75 % of eldery, Additional the adjuvante chemotherapy in 73,3 % of eldery and 39 % young (P=0,007)

10:00 – 10:15 Prof. Feras Alali College of Pharmacy, Qatar University, Qatar

Prof. Feras Alali, Bsc Pharmacy, Jordan University of Science and Technology

(JUST), PhD in Medicinal Chemistry and Molecular Pharmacology, Chemistry of

Natural Products, Purdue University. Since Sept. 2013, Prof. Alali is the Associate

Dean of Research and Graduate Studies, College of Pharmacy, Qatar University. Dr

Alali is world authority in nature-based drug discovery and development. His

research interest spans from novel new anticancer agents to treating stress

associated cognitive impairment. To his credit are 78 international, peer-reviewed

publications, two book chapters and a USA patent. Dr Alai served two term Dean of

Pharmacy and Founder Director of Research Center. Dr Alali was awarded the

Highest National Recognition Award in Science - Pharmacy in Jordan in 2008 (Royal

Decree). Currently, October, 2017, Dr Alali’s Elsevier Scopus h index is 20 with 1765

total citations, ResearchGate h index 22 with 2088 total citations, and Google

Scholar h index of 25 and i10-Index of 46 with 2667 total citations.

7-O-Methylpunctatin: A Homoisoflavonoid Scaffold with

Antimetastatic Potential against MDA-MB-231 Breast Cancer

Cells Alaaeldin I. Saleh1, Tamam El-Elimat2, Ali Eid3,*, and Feras Q. Alali4,2* 1. College of Medicine, Qatar University, Doha 2713, Qatar. 2. Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science

and Technology, Irbid 22110, Jordan 3. Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, Beirut

1107-2020, Lebanon 4. Faculty of Pharmacy, Qatar University, Doha 2713, Qatar


7-O-Methylpunctatin, a recently in-house discovered homoisoflavonoid from the bulbs of Bellevalia eigii Feinbrun (Asparagaceae), was studied for their effects on the proliferation, migration, invasion, metastasis, and tumor growth of triple negative MDA-MB-231 breast

cancer cells. 7-O-methylpunctatin at 20 M was found to inhibit proliferation, migration, and adhesion of breast cancer cells and to attenuate invasion. 7-O-methylpunctatin inhibitory action against migration and invasion could be attributed to induction of cell aggregation, upregulation of occludin, and downregulation of uPA. However, cell adhesion was inhibited via NF-kB downregulation. Additionally, cellular senescence, autophagy, cell cycle arrest, and reactive oxygen species were induced by 7-O-methylpunctatin treatment indicating that 7-O-methylpunctatin exerts its anti-proliferative activity by G0/G1 cell cycle arrest, and caspase pathway activation. MAPK, PI3K/Akt pathways were suppressed upon treating MDA-MB-231 cells, indicating their role in 7-O-methylpunctatin inhibition of migration and invasion. The results obtained in the current study identified 7-O-methylpunctatin as a potential novel therapeutic treatment of breast cancer metastasis that warrants further studies and development.

Session Chairs: Dr.Zehra Bozdak & Dr. Hamid Yahya Husain

10:45 – 11:00 Prof. Moussa Alkhalaf College of Medicine, Qatar University, Qatar

Professor Moussa Alkhalaf was born in Aleppo, Syria, in 1960. He obtained his BSc Biology in 1981. He obtained PhD in Biomedical sciences from the University of Franche Comte in Besancon (France). In 1990, he joined the Department of Cellular and Molecular Biology at the University of Manitoba (Canada) to work on variant estrogen receptors and their role resistance in breast cancer. In 1993, he worked a researcher at the Institute of Genetics and Cellular and Molecular Biology at Luis Pasteur University in Strasbourg University and he developed a transgenic model with mdm2 oncogene. In1998, he joined Kuwait University and he obtained the 2006/2007 Kuwait University Distinguished Researcher Award. His book “the Genomic Era” was awarded the 2006 Best Published Book Prize in the Arab World by Jerash University (Jordan). Currently, he is full professor and serves as the Director of PhD Medical Biochemistry Graduate Program in Department of Biochemistry.

How valuable is BRCA1 evaluation? Mutations pattern in

Kuwaiti breast cancer patients

For decades after the discovery of BRCA1 as one of the genes responsible for the development of breast cancer in women, several questions about its role still unanswered. Data from literatures showed that BRCA1 mutation carriers have a lifetime risk of developing breast cancer in some human populations. However, the role of BRCA1 in other populations including Arab women has not yet been explored. Our study was to analyze the role of BRCA1 mutations in breast cancer women from Kuwait.

DHLPC followed by DNA sequencing were used to analyze BRCA1 sequence variations for 116 unselected breast cancer patients (mean age: 49.15 years, range from 27-76 years) and 119 matching healthy controls (mean age: 47.89 years, range 31-70 years). Around 69% of the


patients have at least one change in their BRCA1 sequence. There was no significant difference in the age of onset between patients having changes in the sequence and patient without sequence changes (48.72 years for patients with sequence changes, 50.18 years for patient with the wild type sequence). Surprisingly, 61% of the healthy controls showed BRCA1 sequence variation as compared to the published BRCA1 sequence. In total, 30 BRCA1 sequence variants were identified in the Kuwaiti breast cancer population. 25 sequence variants were detected at the heterozygote level and five variants were present at the heterozygote and homozygote levels. Most of these variants were also present in healthy controls.

We show here that the spectrum of BRCA1 mutations in Kuwait is different from all studied populations. We observed that Kuwaiti women with certain variants have increased risk for developing breast cancer (p<0.05) and these variants were not known as full mutations. The discrepancy in BRCA1 mutations will be discussed.

11:00 – 11:15 Prof. Mohamed Nizar Akil Faculty of Medicine, Gaziantep University, Turkey

Medical Degree- Faculty of Medicine- University of Aleppo- Syria 1973

C.E.S Degree in Pathology (Histopathology) Pierre & Marie Curie University – Paris - France 1981 Professor of Pathology – University of Aleppo - Syria 1982-2012 Professor of Pathology – Gaziantep University- Turkey 2012 – 2017 Member of International Academy of Pathology (IAP)-Arab division Main interests; GIT, breast, bone and soft tissue pathology. Email; [email protected]

The role and clinical impact of genetic in breast cancer

Breast cancer is the most common malignancy accounting for 29% of all female cancers and responsible for 15% of cancer deaths in women.

Breast cancer is a multifactorial disease, which may involve an interaction between environmental, lifestyle, hormonal and genetic factors. Genetics is estimated to be responsible for 5 to 10 out of 100 cases of breast cancer, but 75% of women with this cancer have no readily identifiable risk factors.

About 5% of all breast cancers are largely attributable to inherited mutations in specific genes including BRCA1, BRCA2 and TP53.

Hereditary breast cancer is usually characterized by early age of onset, a high incidence of bilateral disease and with a family history of other malignancies, nevertheless some cases of “sporadic” breast cancer occur in women who carry a high-penetrance breast cancer susceptibility gene mutation but do not have a family history of breast cancer; other genes, such as PALB2, TP53, PTEN, CDH1, and STK11, confer a risk to either or both of these cancers with relatively high penetrance.

Additional genes, such as CHEK2, BRIP1, RAD51, and ATM, are associated with breast and/or gynecologic cancers with moderate penetrance.



Although such cancer susceptibility genes are very important, highly penetrant germline mutations are estimated to account for only 5% to 10% of breast cancers overall.

11:15 – 11:30 Dr. Elif İşbilen Department of Biochemistry, Gaziantep University, Turkey

Dr. İşbilen received her undergrad education from İstanbul Medicine Faculty in 2003, She then obtained her postgraduate degree from Gaziantep University, Department of Biochemistry in Turkey. She is Currently working as a medical professional and assistant professor at Department of Biochemistry of Gaziantep University. Before that she worked for two years at Ankara University and Ibni-Sina Hospital Biochemistry Department, She also worked for 5 years at Baskent University, Konya Application and Research Hospital

Prognostic Roles of B-Cell Lymphoma 2

(Bcl-2) Expression in Breast Cancer

Hülya Çiçek¹, Mustafa Yıldırım², Özlem Saygılı¹,Elif İşbilen¹, Hasan Ulusal¹ ¹Gaziantep University, Department of Biochemistry ²Bahçeşehir University, Department of Internal Medicine

When breast cancer is diagnosed early, it is very important that the sensitivity of the diagnostic tests is high so that adequate treatment is available, progress can be stopped and complications can be prevented.

In this concept, the relationship between Bcl-2 protein, which plays a vital role in the carcinogenesis process, as a predictor of breast cancer, the sensitivity of Bcl-2 protein, and breast cancer was examined in this study.

Current studies suggest that Bcl-2 is a reliable prognostic marker, especially for hormone receptor (HR) positive breast cancer. Bcl-2 positive breast cancer patients have a better prognosis than overall survival and relapse-free survival. In addition, Bcl-2 exhibits different prognostic features depending on the molecular subtype of breast cancer.

Bcl-2 expression has been shown to be a positive prognostic factor for 5-year relapse-free survival and disease-specific survival in luminal breast cancer.

The patients with histopathologically diagnosed breast invasive ductal carcinoma between 2014 and 2017 in Medicalpark Gaziantep Hospital, were diagnosed and healthy volunteers were included in the study.

The samples obtained from patients and healthy volunteers were studied by ELISA method in Biotek-ELx808 device.

It is found that there is a significant correlation between Bcl-2 levels in the patient-control group (p <0.001). Bcl-2 levels are 478.1 ± 353.6 U / mL (Range 196.7-2554.7) in the patient group and 286.4 ± 106.1 U / mL (Range 31.9-521.6) in the control group.

When the results of this study are evaluated by ROC analysis, it is suggested that Bcl-2 may be used as a marker with a sensitivity of 93% by accepting Bcl-2 as a border value 230 in breast cancer patients.

Keywords: Breast cancer, Bcl-2 protein, apoptosis


11:30 – 11:45 Mr. Ali Pamuk Department of Medical Biochemistry, Gaziantep University

Gaziantep, Turkey

Mr. Pamuk was born in Adana in 1981. After completing his primary and secondary

education in Adana, he moved to Trabzon in order to study at the Chemistry

Department of Karadeniz Technical University in 1999. After graduating from the

University in 2004, he became a high school chemistry teacher, In March 2006, he

went to the United States of America for language training. After staying in the US

for about eight years, he returned to Turkey in August 2013. Ali Pamuk, currently

resides in Gaziantep, is married and has two children.

EXPRESSION AND PURIFICATION OF RECOMBINANT ACTIVE TET

ENZYME IN E.COLI Ali PAMUK, Hülya ÇİÇEK, Khandakar A. S. M. SAADAT

Increasing research on epigenetics in recent years and the inability to explain some of the subjects with genetically, have necessitated the uncovering of epigenetic mechanisms. As a result of the epigenetic studies made, it has been found that the deterioration of the epigenetic mechanisms is associated with many neurodegenerative diseases and especially cancer. DNA methylation is one of the most common epigenetic mechanisms. In recent years, studies have revealed the existence of a protein family called TET, which is responsible for DNA demethylation. These proteins have been shown to actively reverse DNA methylation and to significantly affect the epigenetic control mechanism through the methylcytosine derivatives they form. However, the mechanism of the TET proteins on the highly complex epigenetic changes is still unclear. The kinetic behavior of proteins is thought to be one of these mechanisms of action. One of the most important thing needed at this point is the production of active TET proteins in a large amount in order to study kinetic and mechanistic of TET proteins. In this study, it was aimed to purify the catalytic domain of TET1 protein recombinantly and actively in E. coli bacteria.

Key Words: TET protein, Epigenetics, DNA methylation, DNA demethylation, 5-methylcytosine, 5-hydroxymethylcytosine, Alpha-ketoglutarate enzymes, Non-heme iron enzymes, E. coli, Expression of recombinant protein, Protein purification, SUMO fusion protein.

11:45 – 12:00 Mr. Anas Azzam Ashour College of Medicine, Qatar University, Qatar

Anas Azzam Ashour was enrolled in the College of Medicine of Qatar University in

2015. While he was studying medicine, Anas found interest in research and

especially in the field of cancer. Anas is working on several projects related to the

outcome of water-pipe smoking and human health where he, together with his

colleagues, recently published a paper regarding the effect of WPS during

embryogenesis; meanwhile, they are exploring the outcome of WPS in human

cancer.


Water-Pipe Smoking and Women’s Health: from pregnancy to

breast cancer Anas A. Ashour1*, Mahmoud Y. Haik1*, Khaled W. Sadek1* & Ala-Eddin Al Moustafa1,2 1College of Medicine & 2Biomedical Research Centre, Qatar University, Doha, Qatar Correspondence should be addressed to Ala-Eddin Al Moustafa E-mail: [email protected]; [email protected]

Water-Pipe Smoking (WPS) is the most widespread tobacco use in the Middle-East, and is rapidly spreading globally. This popularity can be attributed to the belief that the WPS is filtered and less harmful than cigarettes, however, previous studies have proven this belief to be inaccurate. Thus, in our lab, we aimed to explore the outcomes of WPS on women’s health focusing on two important aspects which are embryogenesis and breast cancer development. We assessed the effect of WPS during embryogenesis using chicken embryos as a model; on the other hand, two non-invasive breast cancer cell lines were used to explore the role of WPS in breast cancer progression. Our data revealed that WPS can have lethal effects at the early stage of the embryo which was manifested by decelerating the process of angiogenesis as well as deregulating key controller genes of cell proliferation and apoptosis in addition to cell motility. Regarding the outcome of WPS on breast cancer cells, we noted that WPS provokes cell invasion of MCF7 and BT20 cell lines; this is accompanied by a down–regulation of E-cadherin which is considered as a tumor invasion suppressor. Finally, we found that WPS can activate Erk1/Erk2 which could be the main mechanism behind gene deregulations observed during embryogenesis and cell invasion of breast cancer cells. Thus, our data suggest that WPS can have dramatic effect on women’s health from pregnancy to breast cancer development. However, we believe that more studies are necessary to elucidate various aspects of the dramatic effect of WPS on women’s health.

Session Chairs: Dr. Ahmad Ibrahim & Dr. Waleed Arafat

13:30 – 13:45 Dr. Elzem Şen Faculty of Medicine, Gaziantep University, Gaziantep,

Turkey

Dr Elzem Şen is an Assistant Professor in Anesthesiology and Reanimation Department of the School of Medicine, in Gaziantep University, Gaziantep, Turkey. Her research interests reside in the field of cardiovascular anesthesia, transplantation anesthesia and general surgery anesthesia. She visited Universitair Ziekenhuis Gent in Belgium as an observer for three months in 2015. She has 8 international published articles and three national published articles. She has teaching experience of medical student in the area of cardiopulmonary resuscitation.




FOUR-YEAR EXPERIENCE OF PANCREATICODUODENECTOMY AT

GAZIANTEP UNIVERSITY MEDICAL FACULTY HOSPITAL Elzem Sen1, Sitki Goksu1, Ahmet A. Balık2, Ersin Borazan2, Burak Yakar1, Bedri Turhan1 Gaziantep University, Faculty of Medicine, Anesthesiology and Reanimation Department Gaziantep University, Faculty of Medicine, General Surgery Department

Aim: We aimed to present our four-year experience in pancreaticoduodenectomy operations performed in our hospital's operating room.

Material and Methods: A total of 71 patients’ files were evaluated between September 2013 and September 2017, retrospectively.

Results: Twenty-six patients (36.6%) were female and 45 (63.3%) were male, mean age was

61.612.7 years. The mean duration of operation was calculated as 4.21.98 hours. ASA I: 1 (1.4%), ASA II: 39 (54.9%) and ASA III: 31 (43.6%). Pathologically; Adeno Ca 71.8%, Neuroendocrine Ca 7%, Tubulovillous Adenoma 4.2%, Dysplasia 2.8%, Muscular cystic tumor 1.4%, Non-Hodgkin lymphoma 1.4%, Nesidoblastoma 1.4%, Transparent Ca 1.4%, Myoepithelial hematoma 1.4%, serous cystadenoma 1%, Adenosquamous Ca 1.4%, active chronic inflammation 1.4%, adenoma 1.4%, chronic pancreatitis reported as 1.4%. According to Clavien-Dindo classification, low grade (Grade 1-2) complications were seen in 32 (45%) and high-grade complications were in 5 (7%) patients as postoperative complications. Mean follow - up period was 9.12 ± 12.6 months.

Conclusion: Pancreaticoduodenectomy causes serious morbidity and mortality. This surgery which is mostly performed to treat cancer can be performed safely and the results can be accepted with careful patient selection, careful preoperative evaluation, appropriate surgical technique, critical anesthetic care and postoperative intensive care.

13:45 – 14:00 Dr. Gülçin Elboğa Faculty of Medicine, Gaziantep University, Gaziantep,

Turkey

In 2009, Dr. Elboga graduated from Gaziantep University Faculty of Medicine. Between 2010 and 2013, she completed her specialist education at Gaziantep University Medical Faculty Department of Mental Health and Diseases. Between 2011 and 2015 she studied Cognitive and Cognitive Psychotherapy at the Turkish Association of Cognitive and Behavioral Therapies (TACBT). In 2015, he was certified as a Cognitive and Cognitive Therapist by the European Association for Behavioral and Cognitive Therapies, an international academy that assesses this field competence.

Gaziantep between 2015 and 2017. Ersin Arslan Training and Research Hospital completed the mandatory service. At the same time Dr. Elboga tought at Hasan Kalyoncu University Department of Psychology from 2016-2017. In 2017, she was appointed as a teaching assistant to Gaziantep University Medical Faculty Mental Health and Diseases Department. She is currently the President of Gaziantep University Psychiatry Department.


Anxiety, Depression in Carcinoma of Unknown Primary

Patients Undergoing F-18 FDG PET-CT Imaging Procedure Gulcin Elboga*, Elif Karayağmurlu*, Ertan Şahin** * Department of Psychiatry , Gaziantep University ** Department of Nuclear Medicine, Gaziantep University

Background: Many cancer patients accompanied by a high psychiatric morbidity. The distress levels may depend on the type and stage of cancer. Its severity often peak at the initial diagnosis, recurrence, development of treatment-related side effects and with the diagnostic procedures. The aim of this study was to investigate two major mental health disorders, anxiety and depression in carcinoma of unknown primary patients undergoing positron emission tomography-computed tomography (PET-CT).

Methods: Sixty three carcinoma of unknown primary patients (24 male, 39 female) were included in this study. All patients were referred to Nuclear Medicine Department for Fluorine-18 fluorodeoxyglucose (F-18 FDG) PET-CT imaging for the assessment of their malignant or possibly malignant diseases. The Hospital Anxiety Depression Scale and the State and Trait Anxiety Inventory were used to evaluate the anxiety and depression levels in these patients. Descriptive statistics and inferential statistics was performed. SPSS 17.0 was used for analysis. Statistical significance was set at p=0.05.

Results: The mean anxiety and depression scores of The Hospital Anxiety Depression Scale prior to F-18 FDG PET-CT were 8.9 ( ± 3.6) and 6.8 ( ± 3.3), respectively. The mean state and trait anxiety scores of the State and Trait Anxiety Inventory prior to F-18 FDG PET-CT were 40.2 (± 8.3) and 46.5 (± 7.4), respectively. The Hospital Anxiety Depression Scale and the State and Trait Anxiety Inventory anxiety scores were found to be significantly higher in female patients, smokers and in patients hospitalized.

Conclusion: Patients suffering from carcinoma of unknown primary exhibit high levels of anxiety and depression. F-18 FDG PET-CT imaging procedure may at least contribute to patient’s anxiety. Thus, nuclear medicine physicians should examine patients with extreme care in order to reduce this effect most. Sometimes the physicians may not able to prevent some of the effects of cancer. But they have a vital role in recognizing and treating effectively symptoms of anxiety or depression. In this manner, the cost of cancer for human life can be reduced.

Keywords: Anxiety; Depression; carcinoma of unknown primary; PET-CT

14:00 – 14:15 Dr. Neslihan Bayramoğlu Tepe Faculty of Medicine, Gaziantep University, Gaziantep,

Turkey

Dr Neslihan Bayramoğlu Tepe is an Assistant Professor in Obstetrics and Gynecology Department of the School of Medicine, in Gaziantep University, Gaziantep, Turkey. Her research interests reside in the field of general gynecology, perinatology and urogynecology. She visited Hacettepe University Department of Perinatology as an observer for three months in 2016. She has 9 international published articles and 4 national published articles. She has teaching experience of medical student in the area of obstetrics and gynecology.

http://onlinelibrary.wiley.com/doi/10.1002/pon.3660/full

http://onlinelibrary.wiley.com/doi/10.1002/pon.3660/full


DETERMİNATİON THE EXPRESSION LEVELS OF miRNA 204-5P,

miRNA 138-5P AND miRNA 133-3P IN FORMALINE FIXED

PARAFFINE EMBEDDED TISSUE SAMPLES OF ENDOMETRIAL

CANCER AND RELATIONSHIP WITH THE PROGNOSIS

Hüseyin Kurt1, Neslihan Bayramoğlu Tepe1, Özcan Balat1, Zehra Bozdağ2 1) Gaziantep University School of Medicine Department of Obstetrics and Gynecology 2) Gaziantep University School of Medicine Department of Pathology

Aim: In our study, we aimed to elucidate the function of micro RNAs which have been considered as prognostic biomarkers guiding for early diagnosis and individualized therapy of endometrial cancer (EC). In this context, we determined the expression levels of miRNA 204-5p, miRNA 138-5p and miRNA 133-3p in formaline fixed paraffine embedded (FFPE) tissue samples of EC patients and compared the relative differences by considering prognostic factors.

Materials and Methods: This study includes 49 patients with type 1 EC (1.patient group), 35 patients with type 2 EC (2.patient group) which had surgical staging with a diagnosis of EC and 45 patients undergone endometrial sampling for abnormal uterine bleeding (control group) in our clinic between January 2010–December 2014. Expression levels of selected miRNAs were evaluated by qRT-PCR. Then, the prognostic variables of disease were compared with the levels of their expression. Kolmogorov Smirnov, Mann Whitney U, Kruskal Wallis and Dunn tests were used for statistical analysis. A p value below 0,05 was accepted as significant.

Results: miRNA 204-5p expression levels were significantly increased in type 1 EC patients comparing to control and type 2 EC groups (p=0,017 and 0,001 respectively). miRNA 138-5p and 133-3p expression levels were significantly increased in type 1 and type 2 EC patients comparing to control group (p=0,001). But, there were no significant correlation between expression levels and prognostic variables of EC.

Conclusion: This is the first study evaluating the levels of miRNA 138-5p expression in ECs. Our results suggest that these miRNAs might be oncomiRNAs in the molecular pathogenesis of EC.

KEY WORDS: MicroRNA, Endometrium Cancer, Biomarker

14:15 – 14:30 Mr. Yaman AlAhmad College of Medicine, Qatar University, Qatar

Yaman Farid Alahmad was admitted at Qatar University (QU) in 2014, initially as

an Engineering student. By the end of 2014, Yaman transferred and joined the first

batch of the College of Medicine of QU. During his first year at the College of

Medicine, Yaman showed a great interest in medical research. Thus, he joined Dr.

Al Moustafa’s lab where he started his research.


Role of cell phone radiofrequency in head and neck cancer

progression Yaman AlAhmad1,2, Mohamed Badie Ahmed1, Mohammed Aljaber1 & Ala-Eddin Al Moustafa1,2,3 1College of Medicine & 2Biomedical Research Centre, Qatar University, Doha, Qatar; Correspondence should be addressed to Ala-Eddin Al Moustafa E-mail: [email protected]; [email protected] 3Oncology Department, McGill University, Montreal, Quebec, Canada

Head and Neck (HN) malignancies are frequent cancers worldwide. These cancers are characterized by a marked propensity for local invasion and lymph node metastases. The etiology of HN cancers are affected by several factors comprising gene mutations, environmental factors in addition to life style. On the other hand, cell-phones are now in widespread practice and it has been suggested that their use maybe linked to an increased risk of human brain and probably HN cancers. However, the outcome of cell-phone radiofrequency (RF) on HN cancer progression has not been identified yet. Thus, in our lab, we explored the effect of cell-phone RF on HN cancer progression using two models, chorioallantoic membrane (CAM) of the chicken embryo which is the most common model for angiogenesis and two human oral cancer cell lines, SCC9 and FaDu. Our data revealed that cell-phone RF promotes angiogenesis of the CAM of the embryo at seven days of incubation. Meanwhile, we found that cell-phone RF can enhance cell motility and invasion of SCC9 and FaDu cells; this is accompanied by a down-regulation of E-cadherin, which is a major key controller of cell invasion and metastasis. Regarding the mechanism of cell-phone RF on angiogenesis and cell invasion, our study showed that cell-phone RF activate Erk1/Erk2 in our cell line models. This investigation suggests that cell phone RF enhances HN cancer by stimulating angiogenesis and cell invasion via, at least, Erk1/Erk2 activation. Thus, our data imply that cell-phone use in HN cancer patients could have a dramatic effect on their cancer progression

14:30 – 14:45 Prof. Ala-Eddin Al Moustafa College of Medicine, Qatar University, Qatar

Ala-Eddin Al Moustafa has earned his B.Sc. from Aleppo University (Aleppo-Syria)

and his Master as well as PhD in Developmental Biology from Paris XIII University

(Paris-France). Afterwards, he completed his training as a postdoctoral fellow at

McGill University (Montreal-Canada). He was then appointed as a project director

and an assistant professor at the Lady Davis Institute and the Oncology

Department of McGill University, respectively. Dr. Al Moustafa and his Colleagues

from Aleppo University established the first Cancer Research Centre in Aleppo-Syria

within the Syrian Society Against Cancer. He also founded the Middle-Eastern

Association for Cancer Research and its journal, the Clinical Cancer Investigation

Journal. Dr. Al Moustafa published more than eighty papers, in international

journals, and book chapters. His main research focuses on the roles of several

Oncogenes and Onco-viruses in human carcinogenesis and metastasis. In May

2015, Dr. Al Moustafa joined the College of Medicine of Qatar University.




Src/Abl tyrosine kinase inhibitor is a promising molecule for

human papillomavirus-positive cervical cancer therapy Ala-Eddin Al Moustafa1,2,3

1College of Medicine & 2Biomedical Research Centre, Doha, Qatar; 3Oncology Department/McGill University, Montreal, Quebec, Canada E-mails: [email protected]; [email protected]

Cervical cancer is the second most common malignancy in women worldwide. Infection by high-risk human papillomaviruses (HPVs) is the main cause of human cervical cancer. Alternatively, aberrant activation of the non-receptor tyrosine kinases Src and c-Abl contributes to the progression of several human cancers; in addition, it is well-known that EGF-receptor activities are elevated in human carcinomas, including cervical, and are often associated with aggressive cancer. In this study, we compared the effects of SKI-606 with Iressa, Src/Abl and EGF-R kinase inhibitors, respectively, on selected parameters in HeLa and SiHa cervical cancer cell lines, which express E6/E7 onco-proteins of high-risk HPV types 18 and 16, respectively. We reported that SKI-606 and Iressa inhibit cell proliferation and deregulate cell cycle progression in both cell lines. In parallel, we found that SKI-606 induces differentiation to an epithelial phenotype “mesenchymal-epithelial transition”; consequently, SKI-606 causes a dramatic reduction in cell motility and invasion abilities of HeLa and SiHa cancer cells, in comparison with untreated cells and Iressa-treated cells in which these parameters are only slightly affected. These changes are accompanied by a regulation of the expression patterns of E-cadherin and catenins; additionally, SKI-606 clearly down-regulates the expression of P-cadherin, fascin, Id-1, IGF-R1 and EGF-R which are important controllers of cancer invasion and metastasis. The molecular pathway analysis of Src/Abl inhibitor demonstrated that SKI-606 inhibits the phosphorylation activity of -catenin and consequently converts its role from a transcriptional regulator to a cell-cell adhesion molecule. Our data indicate that SKI-606 disturb signaling pathways involved in regulating tumor progression genes via catenin alteration, suggesting that Src/Abl inhibitor, in comparison with EGF-R, is a promising therapeutic agent for human cervical cancer.

Session Chairs: Dr. Mir Faeq Ali Quadri & Dr. Ala-Eddin Al Moustafa

15:30 – 15:45 Prof. Waleed Arafat Faculty of Medicine, Alexandria University, Alexandria,

Egypt

Dr. Arafat obtained his Doctoral and postdoctoral degree and training from the University of Alabama at Birmingham (UAB). He then did a postdoctoral fellowship at St. Jude Children’s Hospital (2003-2004) after which he was a visiting professor at MD Anderson Cancer Institute in 2005. Today Dr. Arafat is professor at the Clinical Oncology Department, Faculty of Medicine, Alexandria University.

Dr. Arafat is a member. Dr. Arafat is a member of several professional national and international associations, including The American Society of Gene Therapy, American Society of Therapeutic radiation & Oncology, American Association of Cancer Research, Society of Clinical Oncology, Egyptian Society




of Cancer, Egyptian Society of Clinical Oncology and Nuclear Medicine, European society of medical Oncology.

Dr. Arafat has over 68 publications in international journals and conferences covering basic science and clinical research. Publications have reached 1040 citations and achieving h-index of 15.

A novel predictive marker of resistance to neoadjuvant

Chemoradiotherapy in young Rectal Cancer patients

W. Arafat, 5 H. Morsy1, A. Gaballah2, M. Samir3, M. Shamseya4, H. Mahrous1, A. Ghazal2, M. Hashish1

1Human Genetics Department, Medical Research Institute, Alexandria, Egypt; 2Microbiology Department, Medical Research Institute, Alexandria, Egypt; 3 Clinical and Experimental Surgery Department, Medical Research Institute, Alexandria, Egypt; 4Clinical and Experimental Internal Medicine Department, Medical Research Institute, Alexandria, Egypt; 5Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Alexandria University.

Objectives: The aim of the study was to delineate the gene expression profile of LGR5 in rectal

cancer (RC) tissues among young Egyptian patients. The study aimed at investigating the

possible link between this cancer stem cells (CSCs) related gene and clinical outcome, including

response to neoadjuvant chemo-radiotherapy (CRT).

Methods: The study was conducted on 30 young Egyptian RC patients, who were

recommended to undergo neoadjuvant CRT. Paired tumor and non-tumor adjacent mucosal

tissues were obtained from patients by routine biopsy techniques. Total RNA was extracted

followed by reverse transcription, then quantitative PCR was performed using SYBR green.

Expression levels of several CSCs related gene including LGR5 in tumor relative to adjacent non-

tumor tissues were calculated using the comparative Cq method after normalization for the

expression of ACTB. Patients were followed up for assessment of response to neoadjuvant CRT

based on revised RECIST 1.1.

Results: Among CSCs genes that are tested, only Overexpression of LGR5 in human RC tissues

compared to non- tumor tissues was detected. Furthermore, correlation analysis showed that

higher expression of LGR5 was correlated with more depth of tumor invasion, LN metastasis,

advanced cTNM stage and mesorectal fascia involvement. On the other hand, it was not

correlated with gender, age, tumor site nor pathological features. These results suggest that

LGR5 may not only play an important role in the progression of RC but also serve as a potential

unfavorable prognostic biomarker for RC. In addition, high LGR5 expression level was

associated with poor response to CRT.

ROC curve analysis showed that LGR5 expression is an excellent predictor for response to

neoadjuvant therapy.

Conclusions:

1- High LGR5 expression is, most likely, indicative of poor prognosis among young Egyptian RC

patients.

2- LGR5 expression level is proposed to be a novel predictive marker of resistance to

neoadjuvant CRT in young Egyptian RC patients.


15:45 – 16:00 Dr. Havva Yeşil Çınkır Faculty of Medicine, Gaziantep University, Turkey

Dr. Çınkır obtained her degree from Hacettepe University Faculty of Medicine in 2006, then she specialized in internal medicine at Cukurova University, and became a specialist in medical oncology from Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital in 2015. Dr. Çınkır is currently an assistant professor at Gaziantep University’s Faculty of Medicine.

The Role of GA-68 PSMA PET / CT in

Evaluating Response to Docetaxel Therapy

in Castration Resistant Prostate Cancer

Patients Havva Yeşil Çınkır1, Umut Elboğa2, Ertan Şahin2, Y. Zeki Çelen2

1Gaziantep University Faculty of Medicine, Medical Oncology, Gaziantep

2Gaziantep University Faculty of Medicine, Nuclear Medicine, Gaziantep

İntroduction: The first treatment option for advanced stage prostate cancer is to stop the

action of androgens in the body, either medically or surgically. The testosterone levels at the

castration level refer to the definition of castration-resistant prostate cancer (CRPC) when PSA

is elevated or new metastases develop. In this case, the chemotherapy regimen containing

docetaxel is usually first tried. Anatomic imaging methods and bone scintigraphy are

inadequate to evaluate the response to docetaxel. In this study, the contribution of Ga-68

PSMA PET / CT in assessing response to docetaxel treatment was investigated.

Methods: We performed Ga-68 PSMA PET / CT imaging in 24 patients with CRPC before

docetaxel treatment. Patients with all metastatic disease were treated 4-6 times with

docetaxel. Patient control Ga-68 PSMA PET / CT imaging was performed to evaluate the

response to treatment. Pre- and post-treatment involvement areas were assessed

semiquantitatively and anatomically, as well as visual assessment, when necessary, with SUV

measurement.

Results: In pre-treatment Ga-68 PSMA PET / CT, pelvic lymph node metastases in 14 patients,

distant lymphatic metastases in 18 patients, skeletal system metastases in 18 patients and

visceral organ metastases in 6 patients were detected in 14 patients as well as intensive

prostate loops in all patients. In the post-treatment evaluation, 16 (66%) of 24 patients were

evaluated as progress disease by monitoring the number, size and Ga-68 PSMA involvement or

new lesions developed in existing lesions. One of the other eight patients had stable disease

and seven had minimal or partial regression.

Conclusion: Ga-68 PSMA is a superior imaging technique for prostate cancer because it

demonstrates the presence of active tumor tissue in PET / CT and allows the possibility to

detect unexpected areas of involvement with whole body imaging. In addition, intensive PSMA

expression in cells in the involvement area helps evaluate the alternative treatment option with

the Lu-177-labeled PSMA molecule in addition to the newer treatments such as abiraterone /


prednisolone, enzalutamide, cabazitaxel and Ra-223 in patients who do not respond to

Docetaxel.

Key words: Prostate, Docetaxel, Ga-68 PSMA PET / CT

16:00 – 16:15 Dr. Ahmad H. Ibrahim Faculty of Sciences, Zakho University, Iraq

Dr. Ahmad obtained his Bachelor of Science degree in Biology, from the University of Baghdad. He subsequently studied at the University of Science Malaysia. Where he obtained his MSc in Cellular and Molecular Biology in 2010. He obtained his Ph.D. in 2014-2015 in Molecular Pharmacology during that time; where he cloned and characterized several genes such as the RNA Helicase gene. Then he started his research at Eman Biodiscovery, School of Pharmaceutical Sciences, and University of Science Malaysia (USM). He later on moved from transcriptional studies to cell signalling, molecular immunology, immunohistochemistry and molecular pharmacology of neurodegeneration disease and neuroprotection sciences at the School of advance Medicine and Dental Sciences at USM. He learned about molecular biology and molecular medicine to the benefits of understanding the molecular basis in human health and drug discovery

.

Neuroprotective efficacy of Cocos nucifera Oil on Mammalian

Cells after Serum Deprivation Chemotactic Grading Oxidative

Stress in The Hypoxia and Ischemia Ailments Ahmad H. Ibrahim1, Ghanem Muhsin Jaafar2, Mohammed Sadeq Al-Ibrahim2, Aman Shah Abdul Majid3 and Amin

Malik Shah Abdul Majid4

1Faculty of Sciences, University of Zakho, Zakho, Kurdistan Region, Iraq; 2Technical Institute of Zakho, Duhok

Polytechnic University (DPU), Duhok, Kurdistan Region, Iraq.3 Pharmacology, Quest International University, Perak,

Malaysia; 4Pharmacology, School of Pharmaceutical Sciences, University of Science Malaysia Pinang, Malaysia.

Email: [email protected]

Introduction: Neurodegenerative diseases can be characterized by progressive neuronal loss

and dysfunction of the nervous system. In optic neuropathies, hypoxia, ischaemia, and

inflammation induce neurodegenerative changes initiated by acute or chronic intermittent

insults including oxidative damage. Current neuroprotection strategies aim to minimize cellular

damage as a result of these processes. Active phytochemicals present in Cocos nucifera oil

extract mixture of active compounds of Polar fatty acid namely Lauric acid, Myristic acid, and

Palmitic acids were utilized.

Objectives: This study aims to evaluate the neuroprotective efficacy of a commercially

developed Fermented Oil, derived from Cocos nucifera.

Methodology: Fermented Oil was screened for its neurotoxic properties on Mammalian Cells,

Retinal Ganglion Cells.



Results: In vitro ischaemia studies revealed 3.1 µg/ml to 50 µg/ml was most effective in rescuing

Retinal Ganglion Cells. Cells from the detrimental effect of: 1) 48hr serum deprivation and 2)

24hr chemical hypoxia exposure of 300 µM cobalt (II) chloride (CoCl2).

Conclusion: FCO thus exhibits its neuroprotective activities by inhibiting ischaemic and hypoxic

in Retinal Ganglion Cells and 2) neutralizing free radicals of Cocos nucifera oil extract mixture

of active compounds of Polar fatty acid namely Lauric acid which constitutes 46.6 %, 21.8 % of

Myristic acid and Palmitic acid 11.5 % were originate.

Keywords: Neuroprotection; Ischaemia, Hypoxia, Retinal Ganglion Cell; and Fermented Cocos nucifera oil.

16:15 – 16:30 Dr. Hale Çolakoğlu Er Faculty of Medicine, Gaziantep University, Turkey

She graduated from University of Gaziantep, School of Medicine with third degree in 2007 . She worked as assistant doctor at Pharmacology Department of Gazi University between December 2007- March 2008. She completed her specialty education at Radiology Department of Ankara University School of Medicine between the years of 2008-2013. She started public service obligation at Gaziantep Şehitkamil State Hospital as a radiology specialist. She worked at State hospital between July 2013 - May 2016. She is an assistant professor in Radiology Department at University of Gaziantep since June 2016. She has several articles, almost all of which were published in SCI-E indexed national or international journals. She is interested in all subjects of diagnostic radiology.

Efficacy of 64 detector computed tomography for the

preoperative staging and resectability evaluation of

pancreatic premalignant and malignant masses Bengi Sarı1, Hale Çolakoğlu Er2, Serdar Akyar3

1 Ankara University, MD, School of Medicine, Department of Radiology, Ankara, Turkey

2 University of Gaziantep, MD, Assistant professor, School of Medicine, Department of Radiology, Gaziantep,

Turkey

3Ankara University, MD, Professor,School of Medicine, Department of Radiology, Ankara, Turkey

Objective: To evaluate the efficacy of a 64 detector CT for preoperative staging and to evaluate

the resectability of malignant and premalignant lesions in patients with pancreatic tumors.

Methods: Patients were included in the current study if they were referred to Ankara University

radiology department between November 2010 and April 2013 for 64 detector CT for the

preoperative staging of suspected pancreatic cancer; further, included patients had a

histopathologically confirmed diagnosis of pancreatic malignant or premalign tumor following

surgery. Twenty-four consecutive patients (12 men and 12 women with a mean age of 53.6

±12years (24–72 years)) who met the aforementioned inclusion criteria were included in this

study.


Results: 46% of 24 patients with malignant pancreatic masses were determined to be localized

(17% Stage 1A, 29% Stage 1B), 50% were locally invasive (12.5% Stage 2A, 37.5% Stage 2B),

and 4% were unresectable (Stage 3). The accuracy rates for T1, T2, T3, and T4 were 100%, 95%,

91%, and 95%, respectively. The sensitivity rates for T1, T2, T3, and T4 were calculated as 100%,

100%, 83%, and 100%, respectively. The specificity rates for T1, T2, T3, and T4 were calculated

as 100%, 94%, 100%, and 95%, respectively. The accuracy, sensitivity, specificity rates in lymph

node staging were 75%, 50%, and 92%, respectively. The accuracy and specificity rates for M

staging were 75% and 92%, respectively. The accuracy, sensitivity, and specificity rates for the

evaluation of preoperative resectability were 91%, 100%, and 91%, respectively.

Conclusion: 64 detector CT is an important method for the diagnosis of and for the

preoperative staging of pancreatic masses.

16:30 – 16:45 Dr. Murat Karaoglan Faculty of Medicine, Gaziantep University, Turkey

I am Murat Karaoğlan. Born 1969 in Gaziantep. Studies of Medicine at the University of Ege (1987-1994); Assistant at the University of Gaziantep Faculty of Medicine, Department of Pediatric(1994-2000); Work experience: I worked as pediatrician between 2000-2011. Vice Head of Gaziantep Children Hospital at 2002-2006. I worked as pediatrician at 2006-2011 at Gaziantep Children Hospital. Assistant at the University of Gaziantep Faculty of Medicine, Division of Pediatric Endocrinology (2011-2014) I worked as Pediatric Endocrinologist between 2014-2017 in Gaziantep Dr. Ersin Arslan Training and Research Hospital. I have been working as Assistant Professor in Division of Pediatric Endocrinology of Gaziantep University Faculty of Medicine since October 2017.

Main fields of interest: Preocious puberty, multiple endocin neoplasia, sex differentiation disorder

From hyperglycemia to hypoglycemia: A Case of Children with

Nesidioblastosis Murat Karaoglan1, Mehmet Keskin1, Emel Aytaç1, Bülent Hayri Özokutan2

1 Gaziantep University, Faculty of Medicine, Department of Pediatric Endocrinology

2 Gaziantep University, Faculty of Medicine, Departmnet of Pediatric Surgery

Abstract: Nesidioblastoma is uncommon, insulin secreting, pancreatic neuroendocrin tumor.

The ductal epithelium differentiates into defective pancreatic βcell, lead to severe, long-

standing hypoglycemia due to hyperinsulinism. It is rarely seem in adolescent. We present a 16-

year-old girl who presented with a diagnosis of metabolic syndrome at the time of first

admission and was diagnosed with nesidioblastosis.

Case Report: A 16-year-old girl presented with complaints and findings of obesity, hirsutism,

menstrual irregularity, low and high blood sugar values measured randomly since eight

months. In her medical history, both hyperglycemia and hypoglycemia were found in the

follow-up of the intermittent blood glucose measurements. On physical examination, Tension

arterial was measured 140/90 mm / Hg. There is widespread hair growth in percentage and


androgen sensitive areas. She was morbidly obese. She had common acanthosis nigricans.

Adrenal CT and pituitary MR were normal. blood glucose values were often higher than 200 mg

/ dL. The patient was diagnosed with metabolic syndrome. occasional hypoglycemia was

accepted as reactive hypoglycaemia.In the past month, however, the patient's hypoglycemia

has become more symptomatic and frequent. Especially after the meal, hypoglycaemic

episodes were evident.

The patient underwent radial echoendoscopy. A hypoechoic nodule with a size of 16 * 14 mm

was found in the pancreas. Of 70% panceras was removed by distal pancreotectomy. Pancreatic

tissue pathology was found to be compatible with nesidioblastosis (Figure 1). Blood sugar was

stable for a short time. After two months, severe hypoglycaemia occured again. Total

pancreatectomy was performed after 6 months. After pancreatoctomy, she had type 1

diabetes.

Discussion: The diagnosis of nesidioblastosis, which is very rare in adolescents and adults, is

very difficult. There are no specific diagnostic methods. Imaging methods provide insufficient

information. Intraarterial calcium stimulation test or somatatin receptor scintigraphy is not

very useful and is often not diagnostic method. The differential diagnosis from insulinoma is

difficult. However, postprandial hypoglycemia may be clinically helpful in differential diagnosis

for diagnosis of nesidioblastosis. Open surgery is mandatory for definite diagnosis and

treatment algorithms. The amount of pancreotectomy is still controversial.

Result: Nesidioblastosis is a very rare cause of hyperinsulinemic hypoglycemia in adults. It is

usually associated with gastric surgery or with insulinoma. The association with the

hyperglycemia such as the metabolic syndrome and type 2 diabetes, is extremely rare.

Therefore, we suggest that in the presence of hypoglycemia in patients with hyperglycemia in

adolescence, it should not be forgotten.

16:45 – 17:00 Dr. Shamal Abduallah Al Muffti Faculty of Sciences, University of Duhok, Iraq

Dr. Al Muffti obtained bachelors degree in plant protection from the University of

Mosul, Iraq in 1981. He went on to study toxicology for his masters, and then

obtained his PhD in molecular biology from the University of Baghdad in 2009. Dr.

Muffti completed his post doctorate training in molecular biology at the College of

Agriculture and natural Resources, of the University of Michigan at the USA.

Dr. Al Muffti is currently the head of the biology department of the Duhok

University, Duhok, Iraq.

Dr. Muffti participated in several national and international conferences and

workshops, and he has more than 20 publications in national and international

journals.


The Impact of Antiapoptotic and Angiogenesis

activity of Fermented Virgin Coconut Oil (FVCO) as

protecting Agent for neurodegeneration disease Ahmad H. Ibrahim1, Shamal Abdulah Mohamad Saeed Al_Muffti2 and Amin Malik Shah Abdul Majid3

1Faculty of Sciences, University of Zakho, Zakho, Kurdistan Region, Iraq.2Faculty of Sciences, University of

Duhok, Duhok, Kurdistan Region, Iraq.3Pharmacology, School of Pharmaceutical Sciences, University of Science

Malaysia Pinang, Malaysia. Email: [email protected]

Introduction: The science of Pharmacology and toxicology provides a broad overview of the

chemicals that have the potential to produce adverse health effects. In our

previous communications, we reported that Fermented Virgin Coconut Oil FVCO possessed

a broad spectrum of proliferative and antioxidant activities. The FVCO is meticulously

extracted through bacteria fermentation process yielding up to 45% extraordinarily pure

lauric acid. Lauric acid is a fatty acid having 12 carbon chains (C12) which is a fat-soluble

organic compound. Objectives: This study was designed to evaluate the FVCO is able to

reduce cell death of retinal ganglion cells (RGC-5) caused by serum deprivation.

Moreover, to show the efficacy of FVCO in promoting angiogenesis for wound healing

application using both in-vitro and in-vivo assays. Methodology Cells were subjected to

serum deprivation and then were treated by using FVCO at different concentrations from

(6-200µg/ml).Various procedures were used to demonstrate the effect of FVCO such as

resazurin fluorescent dye assay, cells morphology, and apoptosis assay. Angiogenesis for

wound healing application using both in-vitro and in-vivo assays. Angiogenesis activity was

assessed by cell migration analysis of human umbilical vein endothelial cells (HUVEC),

microvessel formation using rat aorta ring assay (RARA) and VEGF activity in HUVECs.

Results: The results of this study show that FVCO decreases apoptotic cell death induced by

serum deprivation and significantly increases neuronal viability. Additionally, FVCO

significantly showed stimulation growth of the new blood vessels, stimulated cell migration

at (12.5-25µg/ml). Conclusion: This result exhibits that FVCO acts as a potent wound

healing activity by modulating angiogenesis via upregulation of VEGF, and a good candidate

as a supplement for nerodegeneration disease.

Keywords; ANTIAPOPTOTIC; Angiogenesis; Fermented virgin coconut oil


THE 7TH ANNUAL MEETING OF THE MEACR – GAZIANTEP, UNIVERSITY 37

POSTER PRESENTATIONS

1. Elaeagnus Angustifolia: A promising medicinal

plant for oral cancer therapy

Islam Mohamed1, Ahmed A. Mohamed1, Mennatallah Abdelkader1, Alaaeldin I. Saleh1 & Ala-

Eddin Al Moustafa1,2,3

1College of Medicine & 2Biomedical Research Centre, Qatar University, Doha, Qatar; 3Oncology Department, McGill University, Montreal, Quebec, Canada. E-mail: [email protected]; [email protected]

Introduction: Elaeagnus angustifolia (EA) is a medicinal plant that has been used for centuries in treating many human diseases, in the Middle East, including fever, amoebic dysentery, gastrointestinal problems (1,2). However, the effect of EA plant extract on human cancer progression especially oral malignancy has not been investigated yet. Thus, first we examined the effect of EA flower extract on angiogenesis in ovo, and on selected parameters in human oral cancer cells. Materials and methods: Chorioallantoic membranes (CAMs) of chicken embryos at 3-

7 days of incubation were used to assess the effect EA flower plant extract on

angiogenesis (3). Meanwhile, cell proliferation, soft agar, cell cycle, cell invasion and cell

wounding assays were performed to explore the outcome of EA plant extract on FaDu

and SCC25 oral cancer cell lines. On the other hand, western blot analysis was carried

out to evaluate E-cadherin and Erk1/Erk2 expression and activation, respectively, in

FaDu and SCC25 under the effect of EA extract.

Results: Our data show that EA extract inhibits cell proliferation and colony formation, in addition to the initiation of S cell cycle arrest and reduction of G1/G2 phases. In parallel, EA extract provokes differentiation to an epithelial phenotype “mesenchymal-epithelial transition: MET” which is the opposite of “epithelial-mesenchymal transition, EMT”: an important event in cell invasion and metastasis (4). Thus, EA extract causes a dramatic decrease in cell motility and invasion abilities of FaDu and SCC25 cancer cells in comparison with their controls. These changes are accompanied by an up-regulation of E-cadherin expression. The molecular pathway analysis of the EA flower extract reveals that it can inhibit the phosphorylation of Erk1/Erk2, which could be behind the inhibition of angiogenesis, the initiation of MET event and the overexpression of E-cadherin. Conclusions: Our findings indicate that EA plant extract can downgrade human oral

cancer progression by the inhibition of angiogenesis and cell invasion via Erk1/Erk2

signaling pathways.




2. Vitamin D and Cancer

Ayhan Vurmaz, Sefa Çelik

Afyon Kocatepe University, Faculty of Medicine, Medical Biochemistry Department, Ali

Çetinkaya Campus, 03200-Afyonkarahisar/TURKEY

Vitamin D refers to a group of steroid-like molecules containing cholecalciferol,

ergocalciferol, calcidol and calcitriol. There are two important forms for humans,

ergocalciferol (Vitamin D2) and cholecalciferol (Vitamin D3). While Vitamin D2 is

produced by plants, Vitamin D3 is synthesized from 7-dehydrocholesterol by

exposure to UV radiation in the skin. After being activated in the kidneys, it is

transported through the Vitamin D-Binding Protein (VDBP) to the vitamin D

receptor positive tissues. VDR is a member of the nuclear receptor family, which

includes estrogen receptor, progesterone receptor, androgen receptor. Calcitriol

regulates up to 200 genes directly or indirectly. The inhibitory effect of vitamin D

on angiogenesis, metastasis and invasion, and inflammation reduction,

stimulation of differentiation, apoptotic and antiproliferation activity are

regulated by transcriptional regulation. Vitamin D has a wide range of actions in

many types of cancer. Since most cell lines available for in vitro investigations are

cancer cell lines, studies on the mechanical effects of vitamin D 1, 25 (OH) 2D3 or

analogs are based on the effects of cancer in cancer cells. This makes it difficult to

determine the precise cellular mechanisms that vitamin D may have in cancer

prevention. However, when vitamin D is reported to inhibit angiogenesis,

metastasis, and invasion, vitamin D may play a more specific role in cancer

treatment. Epidemiological studies have shown that there is a high risk of cancer

with low levels of Vitamin D and a relationship between diet and cancer, according

to these studies. The World Health Organization (WHO) states that colon cancer is

associated with vitamin D deficiency. A prospective meta-analysis also revealed an

inverse relationship between serum 25-OHD levels and breast cancer risk in

postmenopausal women. In addition, it alleviates the damaging effects of cancer

by regulating specific signaling pathways in the breast, colon and the similar

tissues.

Key words: Vitamin D, Cancer

3. New cancer treatment strategy: Endoplasmic

reticulum stress

Sefa Çelik, Ayhan Vurmaz




Endoplasmic reticulum (ER) is the main organelle responsible for multiple cellular functions such as protein folding and maintenance of cellular homeostasis. ER stress is activated by a variety of factors and triggers an unfolded protein response (UPR) that either reverts homeostasis or activates cell death. Multiple studies have clarified the link between ER stress and cancer and the role of UPR in particularly. UPR is one of the mechanisms of resistance to cancer treatment, as it regulates the paradoxical microenvironment of cancer. In tumor cells, ER stress may correct homeostasis, and neighboring circulation may provide hospitality for tumor survival and tumor enlargement. During tumor formation, high proliferation rates of cancer cells require increased ER protein folding, assembly, and transplantation, conditions that can induce physiological ER stress. ER stress response is accepted as a cytoprotective and it participates in adaptation to tumor growth and challenging circles. Three ER stress signaling branches localized in ER, inositol requiring enzyme 1α (IRE1α), activating transcription factor 6 (ATF6) and pancreatic ER kinase-like ER kinase (PERK) are involved in tumorigenesis. IRE1α and its down-signaling X-box binding protein (XBP1) contribute to cancer progression. XBP1 is increased in many human cancers such as breast cancer, hepatocellular carcinoma and pancreatic adenocarcinoma. Similarly, another ER stress-related branche PERK/eukaryotic initiation factor 2α (eIF2α)/ATF4 also contributes to cancer progression. The regulation/inhibition of ER chaperones or an arm of the UPR components such as ATF4, XBP1 and PERK has recently been proposed as potential cancer treatments. The accumulation of evidence helps to elucidate the role of ER stress response in tumor development and cancer resistance. Findings from the researches have increased the exciting possibility of targeting UPR components in cancer treatment and can facilitate exploration of the different roles of UPR branches that can produce survival or death signals in tumorigenesis. Key words: Endoplasmic reticulum stress, cancer therapy, unfolded protein response

4. Envitonmental pollutants linked with an increased

risk of cancer in humans

Sefa Çelik, Ayhan Vurmaz, Buğra Koca, Ahmet Kahraman



It has been known that several environmental pollutants are definitely associated

with an increased risk of cancer in humans. In residental life, an increased risk of

mesothelioma has been reported among individuals exposed to asbestos. Many

studies have reported an increased risk of lung cancer due to outdoor air pollution.

Based on the results of the studies, the rate of lung cancer attributable to urban air

pollution in Europe can be as high as 10.7%. A causal relationship has been

established between tobacco use and lung cancer, which may account for 1.6% of

lung cancers. Radon is another source of carcinogens in closed air that can account

for 4.5% of lung cancers. The increased risk for bladder may be due to water


chlorination by products. Exposure to other environmental pollutants, including

pesticides, dioxins and electromagnetic fields, makes available evidence about

cancer risk less satisfactory. In humans, inorganic arsenic in drinking waters plays

an important role in the formation of bladder, skin and lung cancers. Interestingly

several pesticides used in the past have been shown to cause cancers in

experimental animals. The fact that most pollutant-derived cancers arise in the

lungs gives a special perspective to the problem as most of these cancers occur in

smokers and these risk factors can be eliminated.

5. FUNGAL LARYNGITIS: REPORT OF 5 CASES

Ayşe Nur Akatlı1, Hasan Gökçe1, Emine Şamdancı1, Tuğba Bayındır2, Yüksel Toplu2

1 Department of Pathology, İnönü University Faculty of Medicine Malatya, TURKEY

2 Department of Otorhinolaryngology, İnönü University Faculty of Medicine Malatya, TURKEY

Fungal infections of the larynx are considered to be associated with the

immunocompromised patients who are on long-term corticosteroid therapy, or have

chronic systemic diseases, or have undergone organ transplantation, which depends on

immunologic suppression. Clinical similarity to more common lesions like leukoplakia

and carcinoma can cause confusion because fungal laryngitis is an uncommon

condition in immunocompetent patients.

It is important to identify the lesion earlier for the accurate treatment. Diagnosis is made by the demonstration of fungal spores, hyphae or pseudohyphae on tissue biopsy. Demonstration of epithelial hyperplasia with hyperkeratosis, and intraepithelial neutrophils on biopsy should prompt the pathologists to search for fungus by using specialized stains.

We report a series of 5 cases on laryngeal fungal infections diagnosed as candidiasis or aspergillosis, who had a history of smoking and a common initial complaint of hoarseness. Pathologists and clinicians should be aware of fungal laryngitis because they can mimick lesions such as cancer or leukoplakia.

6. Effect of Apoptosis of Calcium Malic Acid Complex

Gökhan CEYHAN1,2, 3*, Bilge ALLI4, Ebru URAS4, Akif Hakan KURT2,3,4

*Corresponding author’s e-mail: [email protected]

1 Kahramanmaraş Sütçü İmam University, Vocational School of Technical Science, Food

Technology, Kahramanmaraş¸ Turkey

2 Kahramanmaraş Sütçü İmam University, Research and Development Centre for

University-Industry-Public Relations, Kahramanmaraş¸ Turkey

3 Kahramanmaraş Sütçü İmam University, Faculty of Medical, Department of

Pharmacology,

Kahramanmaraş, Turkey


4 Kahramanmaraş Sütçü İmam University, Institute of Natural and Applied Sciences

Department of Bioengineering and Sciences, Kahramanmaraş, Turkey

Introduction/Aim: Out of use in beverages and foods are health benefits large

malic acids. In pharmaceutical preparations, L-malic acid can be used to treat

hypertension, low immunity, liver failure and other diseases. However, there is no

data on the effect of Malic acide on colon cancer cell proliferation and apoptosis.

The present study aimed to our synthesized MCa.2H2O2 complexes analyze the

anticancer effects of the on HT-29 colon cancer cells.

Materials and Methods: In this study, new Calcium complex it was extracted by

sumach and characterized by spectroscopic and analytical methods was Ca(II)

complex is pentadentate complex. Molecular structures of the Ca(II) complex was

determined by single crystals X-ray diffraction study. The status of cancer cell line

viability was determined by MTT assay. HT-29 colon cancer cell was treated with

various concentrations (10, 50, 100, 250, 500 µM) of MCa complex in 96-well plates

and incubated for 72 h. Following incubation, MTT solution was added to each well

at a concentration of 0.5 mg/ml, and incubated for 4 h at 37°C. At the end of this

period, 100 µl DMSO solvent was added to each well. The absorbance values at 570

nm of the solution in each well were read using a spectrophotometer.

Results: The results revealed that MCa significantly decreased cell proliferation. In

addition to the antiproliferative effect of MCa, a marked increase in apoptotic

activity was observed when cells were treated with 500 µM MCa complex.

Conclusion: These findings indicate that the new Calcium complex is able to exert

antiproliferative and proapoptotic effects on HT-29 cells.

Key words: Malic acid, Apoptosis, HT-29, Proliferative

7. Differential expression of immunological

markers after anti-PD-1 (Nivolumab) treatment

in a patient with squamous cell carcinoma

Mohammed Ussama Al Homsi1, Maysaloun Merhi1, 2, Afsheen Raza1, 2, Varghese Philipose

Inchakalody1, 2, Abdulqadir Jeprel Japer Nashwan1, 2, Niloofar Allahverdi1, 2, Roopesh

Krishnankutty3, Gianfranco Pittari1, 2, Shahab Uddin3, Abdul Rehman Zar Gul1, Karl Richard

Alexander Knuth1, 2 and Said Dermime1, 2

1National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar

2Translational Cancer Research Facility and Clinical Trial Unit, Interim Translational Research

Institute, Hamad Medical Corporation, Doha, Qatar

3Interim Translational Research Institute, Hamad Medical Corporation, Doha, Qatar

Background: PD-1/PD-L1 checkpoint inhibition has been shown to enhance T cell-

mediated anti-tumor activity, but clinical responses are invariably confined to a fraction


of treated patients. Enriching responding cohorts based on biomarkers of response is a

tempting strategy to improve the clinical outcome of PD-1/PD-L1 blockade. To date,

however, response biomarkers offering binary discrimination of responsiveness have

not yet emerged. NY-ESO-1 is a cancer-testis antigen aberrantly expressed in a variety

of human cancers, known to trigger potent humoral and cellular immune responses. In

this study, we correlated clinical responsiveness to PD-1/PD-L1 blockade and natural

immunity to NY-ESO-1 in a patient with recurrent squamous cell carcinoma (SCC) of

the head and neck. This data has been generated to support the notion, that presence

anti-NY-ESO-1 integrated immunity may potentially identify response to checkpoint

blockade in SCC patients.

Methods: A 71-year-old Qatari male patient was first diagnosed with SCC in 1997. After

initial chemo-radiation, a recurring SCC involving the supraglottic region and tongue

base was identified in 2016. Second-line treatment with Nivolumab, a monoclonal

antibody against PD-1, was started (3 mg/kg every 2 weeks for 5 cycles). Peripheral

blood samples were obtained before Nivolumab and after the 3rd and the 5th cycles of

Nivolumab. A panel of 27 plasma biomarkers was carried out by multiplex analysis. The

antibody response to the NY-ESO-1 antigen was measured in the plasma using ELISA

and Western Blot assays against the NY-ESO-1 protein. The cellular response to the

NY-ESO-1 antigen was investigated in patient’s PBMCs using an ELISPOT assay for IFN-

gamma production by T cells against the NY-ESO-1 protein.

Results: Clinical response to Nivolumab; After the 5th cycle of Nivolumab treatment,

the patient’s bleeding stopped and CT scan follow-up showed stable disease, no

progression or distant metastasis. Determination of anti-tumor immune response; In

the following results we compared data obtained after vs. before Nivolumab treatment.

The cytokine/lymphokine profile data showed that 6 biomarkers were significantly

increased after the 3rd cycle: IL-6 (*p=0.02), IL-8 (*p=0.015), IL-10 (**p=0.007), GM-

CSF (*p=0.014), IFN-γ (***p=0.0006) and TNF-α (**p=0.03). 4 biomarkers were

significantly increased also after the 5th cycle: IL-6 (*p=0.01), IL-10 (*p=0.02), sCD137

(**p=0.04) and IL-1β (*p=0.04). 5 biomarkers were significantly decreased after the 3rd

cycle: Granzyme A (*p=0.01), Granzyme B (**p=0.004), Perforin (*p=0.01), sFAS

(**p=0.005) and IL-17A (*p=0.013). 3 biomarkers were significantly decreased also after

the 5th cycle: Granzyme A (*p=0.03), Granzyme B (**p=0.002), Perforin (**p=0.005),

and IL-17A (*p=0.017). The remaining 13 biomarkers analyzed (IL-2, IL-4, IL-5, IL-7, IL-

12 (p70), IL-13, IL-21, IL-23, MIP-1α, MIP-3α, MIP-1β, ITAC and sFASL) showed no

significant change. ELISA results showed that the NY-ESO-1 antibody titers were

significantly higher before treatment (***p=0.0002) and after treatment (3rd cycle

***p=0.0018; 5th cycle ***p=0.002) compared to healthy control. Interestingly,

Western Blot analysis demonstrated a significant reduction of such responses after

treatment (5th cycle **p=0.0032) and this may be due to tumor shrinkage as indicated

by CT scan examination which showed stable disease. ELISpot results demonstrated

that IFN-γ secretion was significantly increased after the 3rd cycle (*p=0.02) with higher

IFN-γ secretion after the 5th cycle (*p=0.03) of anti-PD-1 treatment.


Conclusion: We have studied the expression of immunological markers before and

after anti-PD-1 treatment in a patient with long and recurrent history of head and neck

SCC and spontaneous immunity to NY-ESO-1. This patient showed a transient

regression and stability of the tumor after anti-PD-1 treatment. The study of

immunological markers in this patient showed a differential expression before and after

anti-PD-1 treatment. We conclude that this immunological monitoring would help in

providing critical understanding of the predictive value of NY-ESO-1 antibody and T cell

response and their upstream and/or downstream cytokines/lymphokines cascade as

biomarkers of response to such treatment.

8. In vitro induction of NY-ESO-1 tumor antigen

expression in lung cancer cells after treatment with 5-

Aza-2'-Deoxycytidine and X-irradiation Varghese Philipose Inchakalody1, 2, Sara Taleb1, 2, Maysaloun Merhi1, 2, Roopesh

Krishnankutty3, Lubna Therachiyil3, Afsheen Raza1, 2, Shahab Uddin3, Alexander Knuth1,

2, Said Dermime1, 2

1National Center for Cancer Care & Research, Hamad Medical Corporation, Doha, Qatar

2Translational Cancer Research Facility, Interim Translational Research Institute, Hamad

Medical Corporation, Doha, Qatar


Background: The capability of the immune system to recognize and kill cancer

cells is dependent on many factors, with the expression of immunogenic target

antigens in cancer cells being one of the prime mechanisms. The NY-ESO-1

antigen is the most immunogenic cancer testis (CT) antigens known to date.

Generally, it is not expressed in normal adult tissues, except in germ cells. The NY-

ESO-1 expression at the cellular level is often heterogeneous depending on the

methylation of the NY-ESO-1 gene. It has been reported that the

chemotherapeutic drug 5-aza-2'-deoxycytidine (5-aza-CdR) enhances the

expression of NY-ESO-1 protein through demethylation of promoter CpG islands.

Radiotherapy is known, on the other hand, to induce de novo protein synthesis

which enhances the expression of NY-ESO-1 protein in cancer cells. We

hypothesized that 5-aza-CdR and radiotherapy would both in vitro induce the NY-

ESO-1 protein in lung cancer cell lines.

Methods: Two lung cancer cell lines (NCI-H522, NCI-H1975) were cultured in the

presence of 5-aza-CdR or X-irradiation and screened for NY-ESO-1 expression. For

5-aza-CdR treatment, 2.5x105 cells were cultured under standard conditions. The

cells were treated with increasing concentrations of 5-aza-CdR (2.5 to 10 μM) for

48 hrs. After treatment, cells were further incubated for 72 hrs. For X-irradiation,

2x106 cells were cultured under standard conditions. The cells were exposed to a

30 Gy dose of X-Rays using RAD source irradiator. After treatment, cells were


further incubated for 72 hrs. The treated cells were analyzed for NY-ESO-1 protein

expression using a cellular ELISA assay. In this, a cell density of 4 x 104/ well were

seeded in a 96-well flat bottom plate and incubated overnight. Cells were then

fixed, blocked and permeabilized. NY-ESO-1 protein expression was detected

using the primary anti-NY-ESO-1 antibody and goat anti-human-HRP as

secondary antibody. The cell lysates from treated samples were further analyzed

by Western Blotting using chemiluminescence. NY-ESO-1 protein bands were

detected using the primary anti-NY-ESO-1 antibody and goat anti-human

antibody as secondary antibody. In addition, a proteomic profiling of the 5-aza-

CdR treated NCI-H1975 was also carried out using label-free mass spectrometry-

based comparative proteomics approach.

Results: Among the lung cancer cell lines (NCI-H522, NCI-H1975), NCI-H522

showed constitutive expression of NY- ESO-1 protein before treatment. Cellular

ELISA resulted in a dose-dependent increase of NY-ESO-1 expression in both cell

lines after 5-aza-CdR treatment: NCI-H522 and NCI-H1975 had the highest

expression (~2-fold and 16-fold respectively) when treated with the highest

concentration (10μM). Using Western Blot analysis, we detected a band of NY-

ESO-1 protein at 18 kDa in both cell lines after treatment with 5-aza-CdR. X-

irradiation resulted in a 2-fold increase in the expression of NY-ESO-1 in both cell

lines. Comparative proteomics profiling of the 5-aza-CdR treated vs. untreated

cells identified a number of proteins with differential expression and their

functions are being analyzed using functional annotation (DAVID) analysis.

Conclusion: Our data demonstrated that treatment of lung cancer cells with either

5-aza-CdR or X-irradiation resulted in an increase in the expression of NY-ESO-1

tumor antigen. This suggests that the treatment with 5-aza-CdR or X-irradiation

will induce and amplify the expression of NY-ESO-1 in lung cancer cells leading to

a better stimulation of T- cells against this immunogenic antigen. Potential use of

such therapy would be a novel strategy for the treatment of NY-ESO-1 associated

lung cancers.

9. Blocking of PD-1 protein enhances functional

activity of Viral specific T cells generated for

the treatment of viral infections after

allogeneic hematopoietic stem cell

transplantation

Maysaloun Merhi1, 2, Mohammad Bakr1, Ibrahim Al-Hijji1, Gianfranco Pittari1, 2, Munir Jalis1,

2, Shahab Uddin3, Alexander Knuth1, 2, Said Dermime1, 2

1National Center for Cancer Care & Research, Hamad Medical Corporation, Doha, Qatar


2Translational Cancer Research Facility, Interim Translational Research Institute, Hamad

Medical Corporation, Doha, Qatar


Background: Viral infection represents a major cause of disease and mortality after

allogeneic hematopoietic stem cell transplantation (AHSCT) for hematologic

malignancies. It has been shown that adoptive transfer of specific T cells generated

against virus-associated antigens is capable of treating infections that are resistant to

conventional therapies. We have standardized a rapid, cost-effective and highly

efficient protocol for expanding virus-specific T cells (VSTs). These expanded VSTs

showed high specificity to the most immunodominant viral antigens. Although these

VSTs were shown to possess prominent levels of cytotoxic and effector markers, they

also expressed the programmed cell death protein (PD-1). PD-1 is an immune-inhibitory

receptor expressed on the surface of T cells and it is known to induce T cells exhaustion

and inactivation and this may lead to the ineffectiveness of such VSTs after infusion in

patients receiving AHSCT. To this end, we have used an anti-PD-1 antibody to block this

molecule during the expansion of such VSTs and analyzed the effect of this treatment

on T cells phenotype and functional activity.

Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats

of 3 healthy donors (D1, D2 and D3). To expand VSTs, PBMCs were stimulated in G-Rex-

10 flasks with a Master Pepmix containing a pool of 11 overlapping peptides libraries

spanning Epstein Barr virus (EBV), Adenovirus (AdV), Cytomegalovirus (CMV),

Polyomavirus (BKV) and Human Herpes virus (HHV6) antigens in the presence of two

cytokines, IL-4 and IL-7. To investigate the effect of anti-PD-1 treatment, we have

selected one of our healthy donors (D1). Therefore, PBMCs were isolated from D1

peripheral blood and 4 G-Rex-10 flasks were prepared and cultured with the same

cytokines and viral Pepmix as above. 3 flasks received one dose of the anti-PD-1

antibody (1μg/ml) one time at days 2, 5 or 8 and the remaining flask was not treated.

All the VSTs were collected at day 11. We used an ELISpot assay to measure IFN-γ

production by T cells after challenge with the Master Pepmix as well as the individual 11

Pepmix antigens. Flow cytometry analysis was used to phenotype these VSTs. Cells

proliferation and cytotoxicity were determined using BrdU incorporation and Calcein

AM assay respectively.

Results: 3 VST cell lines were generated after 11 days of culture with an expansion

power of 9-folds (9x106 to 77x106 cells) for D1, 11-folds (12x106 to 133x106 cells) for D2

and 7-folds (11x106 to 79x106 cells) for D3. These VSTs produced specific IFN-γ to most

of the viral antigens (7/11 antigens for D1 and 10/11 antigens for D2 and D3) and showed

high proliferative and cytotoxic activities to the viral peptides. Expanded VSTs were

CD3+ T cells (98±0.5%) in which CD4+ T cells were dominant (64±9%). Importantly, they

were mostly of the central memory cell population (CD45RO+ CD62L+; 73±2%).

However, these VSTs expressed high levels of the PD-1 antigen (48±14%). Interestingly,

VSTs treated with anti-PD-1 showed differential expression of phenotypic markers and

functional activity only after treatment at day 5: IFN-γ secretion against the Pepmix was


significantly decreased (***p=0.0008); there was a 1.2-fold increase in the CD4+ T cells

and a 2-folds decrease in the CD8+ T cells; The percentage of naïve CD45RA+ T cells

was decreased by 4-folds; PD-1 expression was increased in both central CD45RO+

CD62L+ and effector CD45RO+ CD62L- memory T cells (1.5 and 1.7-folds respectively),

whereas, PD-1 expression was declined by 2-folds in the CD8+ T cells. Importantly, the

expression of T cells cytotoxicity (CD107) and activation (CD278) markers were

increased after anti-PD-1 treatment (2 and 1.7 folds respectively). This indicates that

the PD-1 molecule was induced by day 5 of VSTs expansion and using anti-PD-1 at that

time modulated the VSTs phenotype and activity.

Conclusions: We have standardized an in vitro protocol for rapid expansion of VST cell

lines with anti-viral specificity to the most immunodominant viral antigens expressed

by viruses causing infection after AHSCT. These VSTs were shown to highly express the

T cells negative regulator PD-1 antigen that induces T cells exhaustion and inactivation.

A preferential expression of both phenotypic and functional T cells markers was

recorded in these VSTs after treatment with anti-PD-1 antibody at day 5 of T cell

expansion. Our findings demonstrated that blocking PD-1 on VSTs would improve the

cytotoxicity and activation of these T cells and help to reverse T cells

exhaustion/dysfunction leading to a long-lasting specific antiviral activity in patients

undergoing AHSCT. Further investigations are being carried out to confirm these

results.

10. The Diagnostic Role Of Caveolin, Hmgb1 And

Endocan Levels In Non-Small Cell Lung Cancer

(Group Of Basic And Clinical Research)

Hülya Çiçek1, Gülper Nacarkahya2, Hasan Ulusal1, Aykut Bahçeci3, Havva Yeşil Çınkır4,

Necla Dirier5, Füsun Tuşgül2, Zeliha Yıldırım2, Özlem Nuray Sever6, Dinç Süren7, Vildan

Kaya8, Ömer Aydın Yıldırım9, Nuri Orhan10, Burak Bilgin11, Aslan Güzel12, Mustafa

Erdoğan13, Mustafa Yıldırım14

1Gaziantep University Faculty of Medicine, Biochemistry, Gaziantep

2Gaziantep University Faculty of Medicine, Medical Biology and Genetics, Gaziantep

3Dr. Ersin Arslan Training and Research Hospital, Medical Oncology, Gaziantep


5Sanko University, Pharmacology, Gaziantep

6Medical Oncology, Gaziantep

7Antalya Training and Research Hospital, Pathology, Antalya

8Medstar Antalya Hospital, Radiation Oncology, Antalya

9Medicalpark Hospital, Internal Medicine, Gaziantep

10Medicalpark Hospital, Biochemistry, Gaziantep

11Medicalpark Hospital, Ophthalmology, Gaziantep

12Medicalpark Hospital, Brain and Neurosurgery, Gaziantep

13Medicalpark Hospital, Cardiovascular Surgery, Gaziantep

14Medicalpark Hospital, Medical Oncology, Gaziantep


Introduction: Lung cancer is the leading cause of cancer-related deaths. There are

two basic histological types of lung cancer, small cell lung cancer (SCLC) and non-

small cell lung cancer (SCLC). NSCLC accounts for 80-85% of all cases. Despite

improvements in treatment, the prognosis of the disease is poor. Due to the fact

that the prognosis is bad, intensive researches continue for early diagnosis and

treatment. Caveolae are invaginations of the plasma membrane in 50 to 100 nm

omega form, which act as regulators of signal transduction.

Caveolins are a class of oligomeric structural proteins that are both necessary and

sufficient for caveolae formation. Interestingly, caveolin-1 is involved in oncogenic

cell transformation, tumorigenesis and metastasis pathogenesis.

High mobility group box (HMGB) proteins are non-histone nuclear proteins with

very different functions in the cell. There is increasing evidence for the role of

HMGB1 in cancer progression, angiogenesis, invasion and development of

metastases. Studies suggest that HMGB1 may have an important role in cancer

development.

Endocan, previously termed endothelial cell-specific molecule-1, is a 50 kDa

soluble proteoglycan consisting of a mature polypeptide of 165 amino acids and a

single dermatan sulfate chain covalently linked to the serine residue at position

137. Expressed in vascular endothelium, this dermatan sulfate proteoglycan is

freely circulating in the bloodstream of healthy individuals. Recently, Endocan

mRNA levels have been recognized as one of the most important molecular

signatures that cause poor prognosis in various types of cancer, including lung

cancer.

In our study, the diagnostic role of Caveolin, Hmgb1 and Endocan levels measured

in serum for small cell lung cancer was investigated.

Materials And Methods: In the Medicalpark Gaziantep Hospital Medical Oncology

Clinic, between 2014 and 2017, patients diagnosed with small-cell carcinoma

diagnosed as histopathologically confirmed and healthy volunteers were included

in the study. Patient files were scanned and information such as age, gender,

routine laboratory tests were obtained retrospectively. Blood samples remaining

from the blood samples of patients for routine checks were collected prospectively

directly before the start of first-line systemic chemotherapy. They were

centrifuged for 15 min at 1,000g within 1 hr of collection. The resulting sera were

aliquoted into microtubes and either immediately frozen at -80 C. These samples

were taken to the refrigerator at 4 ° C temperature overnight before

measurements were taken. Serum samples were allowed to stand at room

temperature for 2 hours before being run by the ELISA method. The samples were

then subjected to measurement procedures with mixing using vortex. Caveolin,

Hmgb1 and Endocan serum levels were investigated using Elisa method.

Statistical analyses were performed using SPSS for Windows 15.0 software. The

normal distribution suitability of the interchanges was examined using visual


(histogram and probability plots) and analytical directions (Kolmogorov-Smirnov /

Shapiro-Wilk tests). In the Kolmogorov-Smirnov test, cases, where the p-value was

above 0.05, were found as the normal distribution. When normal distribution was

not determined, the patient and control group were compared using the Mann-

Whitney U test.

Results : A total of 42 participants were enrolled in the study, 19 (45.2%) patients

and 23 (54.8%) healthy volunteers. Caveolin was found in the patient group as 48.3

± 84.1 (Range 5.5-250) ng / ml, Hmgb1 3.15 ± 3.14 (Range 0.08-12.18) ng / ml and

Endocan 250.7 ± 180.5 (Range 36.2-789.6) ng / L. In the control group, caveolin was

determined as 26.4 ± 38.9 (Range 3.46-176.8) ng / ml, Hmgb1 2.98 ± 2.79 (Range

0.39-8.83) ng / ml and Endocan 301.2 ± 174.6 (Range 109.8-722.6) ng / L. Since

caveolin levels did not show a normal distribution, the patient and control group

were compared using the Mann-Whitney U test. There was no statistically

significant difference between the patient and control groups in terms of caveolin

levels (p = 0.471). Since Hmgb1 levels did not show a normal distribution, the

patient and control group were compared using the Mann-Whitney U test. No

statistically significant difference was found between the patient and control

group in terms of Hmgb1 levels (p = 0.919). Since Endocan showed no normal

distribution, the patient and control group were compared using the Mann-

Whitney U test. No statistically significant difference was found between patient

and control group in terms of Endocan levels (p = 0.283).

Discussion: In our study, no correlation was found between caveolin, Hmgb1 and

Endocan levels and small extracellular carcinoma measured in serum.

Nevertheless, we think that the search for a new marker for early diagnosis and

treatment of this disease, which is common in the community, should be

continued.

Key Words: Caveolin, Endocan, Hmgb1, Lung Carcinoma

11. The Diagnostic Role Of Caveolin, Hmgb1 And

Endocan Levels In Colon Carcinoma: (Group

Of Basic And Clinical Research)

Hülya Çiçek1, Gülper Nacarkahya2, Hasan Ulusal1, Aykut Bahçeci3, Havva Yeşil Çınkır4, Necla

Dirier5, Füsun Tuşgül2, Zeliha Yıldırım2, Özlem Nuray Sever6, Dinç Süren7, Vildan Kaya8, Ömer

Aydın Yıldırım9, Nuri Orhan10, Burak Bilgin11, Aslan Güzel12, Mustafa Erdoğan13, Mustafa

Yıldırım14

1Gaziantep University Faculty of Medicine, Biochemistry, Gaziantep

2Gaziantep University Faculty of Medicine, Medical Biology and Genetics, Gaziantep

3Dr. Ersin Arslan Training and Research Hospital, Medical Oncology, Gaziantep


5Sanko University, Pharmacology, Gaziantep


6Medical Oncology, Gaziantep

7Antalya Training and Research Hospital, Pathology, Antalya

8Medstar Antalya Hospital, Radiation Oncology, Antalya

9Medicalpark Hospital, Internal Medicine, Gaziantep

10Medicalpark Hospital, Biochemistry, Gaziantep

11Medicalpark Hospital, Ophthalmology, Gaziantep

12Medicalpark Hospital, Brain and Neurosurgery, Gaziantep

13Medicalpark Hospital, Cardiovascular Surgery, Gaziantep

14Medicalpark Hospital, Medical Oncology, Gaziantep

Presenter: Havva Yeşil Çınkır

Introduction: Colon cancer is the third most common cancer among all cancers in

terms of both frequency and cancer-related deaths. According to 2006 data, the

incidence in Turkey is second in women and fifth in men. Colonoscopy and fecal occult

blood test are used as diagnostic tools in the early diagnosis of colon cancer. In addition

to these diagnostic tools, studies of serum marker development are maintain their

popularity.

Caveolins are a class of oligomeric structural proteins that are both necessary and

sufficient for caveolae formation. Interestingly, caveolin-1 has been implicated in the

pathogenesis of oncogenic cell transformation, tumorigenesis, and metastasis.

Caveolae are plasma membrane specializations that contain the structural proteins

caveolins, and appear to be important for normal signal transduction. The caveolin

scaffolding domain interacts with several signaling molecules, sequestering them in the

absence of activating signals and thereby reducing the signal-to-noise ratio. Deletion

and mutation of genes that encode caveolins are implicated in the pathogenesis of

several human diseases. Down-regulation of caveolin-1 protein expression leads to

deregulated signaling and consequently tumorigenesis.

High mobility group box (HMGB) proteins are non-histone nuclear proteins that have

very different functions in the cell. The evidence is increasing that HMGB1 plays a key

role in cancer progression, angiogenesis, invasion and metastasis. Studies suggest that

HMGB1 may have an important role in cancer development.

Endocan, previously termed endothelial cell-specific molecule-1 is a 50 kDa soluble

proteoglycan composed of a mature polypeptide of 165 amino acids and a single

dermatan sulfate chain covalently linked to the serine residue at position 137. This

dermatan sulfate, proteoglycan is freely circulating in the bloodstream of healthy

individuals and expressed in vascular endothelium. Experimental evidence suggests

that endocan is a key player in the regulation of major processes such as cell adhesion,

inflammatory disorders and tumor progression.

In this study, we investigated the diagnostic role of Caveolin, HMGB1 and Endocan

levels that measured in serum for colon cancer.


Materials And Methods: Patients diagnosed with histopathologically confirmed

colorectal cancer in the Medicalpark Gaziantep Hospital Medical Oncology Clinic

between 2014 and 2017 years and healthy volunteers were included in the study.

Patient files were screened and information such as age, gender, routine laboratory

tests were obtained retrospectively.

Blood samples were collected prospectively directly prior to the start of systemic

chemotherapy. They were centrifuged for 15 min at 1,000g within 1 hr of collection. The

resulting sera were aliquoted into microtubes and either immediately frozen at -80 0C.

These samples were placed in the refrigerator at 4 0C temperature one night before the

measurements.

The serum samples were allowed to rest at room temperature for 2 hours before

working with the ELISA method. Later, measurement procedures were implemented

by mixing the samples using vortex. All concentration/absorption graphic curves of

research parameters such as Caveolin, HMGB1 and Endocan and calculations on the

results were conducted on a program of the device Biotek_ELx808 (Winooski, Vermont,

ABD).

Statistical analyses were performed using SPSS for Windows 15.0 software.

Conformance of the variables to the normal distribution was analyzed using visual

(histogram and probability graphics) analytic methods (Kolmogorov-Smirnov/Shapiro-

Wilk tests). In the Kolmogorov-Smirnov test, cases, where the p-value was above 0.05,

was accepted as the normal distribution. Groups were compared using the Mann-

Whitney U test when normal distribution was not determined. Results were

represented as the mean ± standard deviation.

Results: A total of 53 participants were included in the study, 30(56.6%) patients and

23(43.4%) healthy volunteers. Caveolin was determined as 58.5±106.2 (Range 0.80-

411.8) ng / ml, HMGB1 3.47±5.31 (Range 0.11-26.03) ng / ml and Endocan 307.5±269.2

(Range 74.2-1203.2) ng / L in the patient group. In the control group, caveolin was

determined as 26.4±38.9 (Range 3.46-176.8) ng / ml, HMGB1 2.98±2.79 (Range 0.39-

28.83) ng / ml and Endocan 301.2±174.6 (Range 109.8-722.6) ng / L.

The patient and control groups were compared using the Mann-Whitney U test because

of caveolin levels were not normally distributed. There was no statistically significant

difference between the patient and control groups in terms of caveolin levels (p =

0.971).

Since HMGB1 levels did not have the normal distribution, the patient and control

groups were compared using the Mann-Whitney U test. There was no statistically

significant difference between patient and control group in terms of HMGB1 levels (p =

0.936).


Since Endocan levels did not have the normal distribution, the patient and control

group were compared using the Mann-Whitney U test. There was no statistically

significant difference between the patient and control groups in terms of endocan

levels (p = 0.355).

Discussion: In our study, no correlation was found between serum caveolin, HMGB1

and endocan levels and colorectal cancer. However, we think that the search for a new

marker should be continued in the case of this common disease in the society.

Key Words: Caveolin, Colon carcinoma, Endocan, Hmgb1

12. Expression Analysis of PBRM1 and BAP1 Genes in

Prostate Cancer

Rozhgar A. KHAILANY1,2, Naser GILANI1,3, Belan KANABE4, *Kübra OKÇU5, Khandakar

A. S. M. SAADAT1

1Department of Medical Biology and Genetics, Faculty of Medicine, Gaziantep University,

Gaziantep, Turkey; 2Department of Biology, College of Science, Salahaddin University,

Erbil, Iraq; 3Farabi Molecular Diagnostic Laboratory, Erbil, Iraq; 4Department of Biology,

Gaziantep University, Gaziantep, Turkey; 53rd Grade Undergraduate Student, Faculty of

Medicine, Gaziantep University, Gaziantep, Turkey.

Prostate cancer (PC) is the second commonest diagnosed malignancy and the fifth

leading cause of cancer mortality in men, and represents a substantial public

health burden. Etiology of prostate cancer remains largely unknown. Indeed, the

only well-established risk factors to date are age, ethnicity and a family history of

prostate cancer. The goal of this study is to evaluate the expression level of PBRM1

and BAP1 in prostate cancer tissues. PBRM1 gene, a tumor- suppressor gene,

which is encodes the BAF180 protein, a chromatin targeting subunit of a SWI/SNF

chromatin remodeling complex, which is involved in transcriptional activation and

repression of selected genes. PBRM1 acts as a negative regulator of cell

proliferation. BAP1 gene provides instructions for making a protein called ubiquitin

carboxyl-terminal hydrolase BAP1 (shortened to BAP1). This protein functions as

a deubiquitinase, which means it removes a molecule called ubiquitin from certain

proteins. In the current study, PBRM1 and BAP1 of 31 paired tumor and normal

tissue samples that were grouped according to the clinical characteristics of

patients were determined by quantitative real-time polymerase chain reaction

(qRT-PCR) technique. Expression level of PBRM1 and BAP1 were significantly

decreased (down-regulated) in prostate cancer compared to normal tissues.

Consequently, Patients with discordant BAP1 or PBRM1 expression across their

matched primary and metastatic tumors usually showed loss of expression during

progression to metastatic prostate cancer.

key words: Prostate Cancer, PBRM1, BAP1, Expression analysis, qRT-PCR.


13. The effect of smokeless tobacco on oral

cancer in the Middle Eastern and North African region: A systematic review

Mir Faeq Ali Quadri 1; Tenny John 2 and Santosh Kumar Tadakamadla 3

1Course Coordinator, Evidence Based Dentistry, Department of Preventive Dentistry, Jazan

University, Saudi Arabia

2Assistant Professor, Department of Maxillofacial Surgery and Diagnostic Sciences, Jazan

University, Saudi Arabia

3Research Fellow, Menzies Health Institute Queensland, Griffith University, Queensland,

Australia

Introduction: A rate-per-year projection analysis, revealed that the incidence of oral

cancer will be doubled in MENA region by the year 2030.

Aim: To systematically review the literature on the effect of smokeless tobacco on oral

cancer in Middle Eastern and North African region.

Materials and Methods: Reporting of this systematic review comprehend the

Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)

guidelines. PubMed, Web of Science, Cochrane and CINAHL databases were searched

using organized combinations of MeSH terms and keywords. Only articles

demonstrating relationship of oral cancer with smokeless tobacco or khat were

included. Quality assessment of included articles was performed using Newcastle

Ottawa Score.

Results: Initial search retrieved 87 titles (PubMed = 51, Web of Science = 32, Cochrane

= 0, CINAHL= 4); and 59 remained after removing the duplicates. Ten articles satisfied

the eligibility criteria. Among these, five articles studied the effect of smokeless

tobacco on the occurrence of oral cancer and all reported a greater prevalence of oral

cancer in tobacco users than non-users. One study from Yemen evaluated the effect of

tobacco and khat usage on oral Leukoplakia and reported a dose-dependent

association between use of khat, Shammah on Oral Leukoplakia. None of the studies

received the highest possible stars which demonstrate that they were not of high

quality.

Conclusions: Shammah users are at higher risk of oral cancer than non-users. As the

studies were of low quality which were conducted on small sample sizes, this conclusion

should be interpreted with caution.

Keywords: Oral cancer; Smokeless tobacco; Middle East; Shammah


14. COMMON CAUSES OF POSTMENOPAUSAL

BLEEDING: SINGLE CENTER 5-YEARS EXPERIENCE

Neslihan Bayramoğlu Tepe1, Zehra Bozdağ2, Hüseyin Çağlayan Özcan1, Denizhan

Bayramoğlu3, Aynur Mustafa1

Gaziantep University School of Medicine, Department of Obstetrics and Gynecology

Gaziantep University School of Medicine, Department of Pathology

Gaziantep Av. Cengiz Gökçek Obstetrics and Gynecology Hospital

Aim: In our study, we aimed to classify the common causes of postmenopausal

bleeding (PMB), to determine whether the causes in Western countries differ or

not, and whether there is a change in the etiologic factors of PMB according to

years.

Method: Patients who applied to Gaziantep University Faculty of Medicine,

Department of Obstetrics and Gynecology Clinic between June 2012 and July 2017

with complaints of PMB and who underwent endometrial sampling by dilatation &

curettage (D & C) were included in the study. The patients' ages, pregnancy

numbers, menopausal periods, hormone replacement therapy (HRT), and D & C

results were retrospectively scanned and recorded. The patients' ages, number of

pregnancy, status of menopaus and hormone replacement therapy (HRT), D & C

results were retrospectively scanned and recorded. Patients who had vaginal

bleeding due to cervical lesions were excluded from the study. Patients who had

D&C before the past 2,5 years were grouped as group A and in the 2,5 years were

grouped as group B. Patients were classified as polyp, atrophy, hyperplasia,

endometritis, drug effect, endometrial cancer, myoma, gestational trophoblastic

disease (GTD) and insufficient material according to D & C results.

Results: The mean age of 760 patients taken into the study was 59.65 years (min:

50, max: 90), mean pregnancy numbers were 4.56 (min: 0, max: 12) and mean

menopause duration was 11.83 years (min: 1, max: 43). One hundred and ninety

seven (%25.9) patients were diagnosed as polyp, 148 (%19,5) patients were

atrophy, 99 (%13,02) patients were hyperplasia, 85 (%11,2) patients were

endometritis, 83 (%10,9) patients were endometrial cancer, 67 (%8,8) patients

were drug effect, 2 (%0,3) patients were myoma and 2 (%0,3) patients were GTD.

In 77 (10.1%) patients, pathology was reported as ‘inadequate material’.

In contrast with the rate of malignancy was decreased (A: %13.45, B: %8.19), the

rates of drug effects (A: %7.1, B: %10.6) and hyperplasia (A: %11.92, B: %14.20)

were increased during the last 2,5 years. There was no statistically significant

difference between these results.

Conclusion: Unlike western societies, the most common cause of PMB was polyps

in our community. In recent years, awareness of the community and early

application to the hospital has reduced the frequency of malignancy with

screening programs in the field of health, but the number of patients with HRT and


hyperplasia is increasing. For this reason, sampling with D & C would be

appropriate to exclude possible malignancy with a PMB patient.

Keywords: Endometrial cancer, dilatation, curettage, postmenopausal bleeding.

15. Jordan Cancer Registry (JCR) Data 2010-2014;

Surveillance for Jordan Cancer Burden.

Omar Nimri, MD.

Background: Cancer registry is an important tool for any successful cancer control

program. The cancer related data from Jordan was vague scarcity. This, urged scholars

to set up the first and only population-based cancer registry in Jordan. Which did the

Ministry of health and the Middle East Cancer Consortium_MECC- established it jointly.

The Registry started to collect data from cases of cancer referred to the treatment and

diagnostic facilities throughout the country to improve cancer reporting in the country

and define the size of the cancer problem and the pattern of cancer in Jordan;

distribution of cancer by geographical locations; age; gender; type and cancer sites for

both Jordanians and non-Jordanians.

Methods: The JCR collects cancer data in passive and active methods of case finding,

the collected data coded by means of ICD_O3. Quality control measures applied and

the data stored and computerized using CanReg_4 and CanReg_5; then analyzed

statistically. World standard population for age adjustment and standardization to

facilitate national and international comparison and contrast.

Results: Incidence of the most common cancers among Jordanians, distributed by Site,

Age, Gender, and geographically for the period 2010-2014. The leading cancer among

adults, males was Colorectal (11.9 %) followed by Lung (11.7 %), Leukemia (9.1 %),

Urinary Bladder (8.9 %) and Prostate (8.1 %). While among female cancers are Breast

(34.4 %), Colorectal (9.4 %); Leukemia (6.7 %); Lymphomas (5.8%) and Thyroid (5.3 %).

Childhood cancers were about (4.9%) of all cancers; Leukemia was 1st (34.8 %) followed

by Brain &CNS (20.9%) and Lymphomas (17.5%).

Whereas the most recent mortality data showed lung is responsible for (21.03%) deaths

among males followed by Colorectal (11.0 %) and Leukemia (8.02%). Among females

Breast deaths (26.8%); Colorectal (9.3%) and Leukemia (7.2%).

Conclusion {Use of the data}: Knowledge to action, based on The JCR data, Jordan

started the Jordan Breast Cancer Program for early detection and screening of Breast

Cancer.


16. Tumor-to-Tumor Metastasis: Case Report of Large

Cell Neuroendocrine Carcinoma of Lung,

Metastasizing to Renal Oncocytoma

Metin KARAKOK , Omer Faruk DİZİBUYUK, Zehra BOZDAG

Gaziantep University, Department of Pathology, Gaziantep, Turkey

Distinct metastatic disease within a second primary tumor, tumor-to-tumor

metastasis (TTM), is a very rare phenomenon. Lung cancer metastasis to renal cell

carcinoma represents the most common combination of such TTM. Oncocytoma

can also serve as a recipient site for TTM, and less than 10 cases has been described

in the literature.

A 60-year-old man with a history of large cell neuroendocrine carcinoma of lung

has been operated because of mass in left kidney discovered on PET CT scanning.

On microscopic evaluation, the tumor showed histologically two distinct areas

.There were typical areas of oncocytoma consisted of round to poligonal cells with

abundant densely granular eosinophilic cytoplasm, round uniform nuclei.

Immunohistochemically these cells showed positive reaction with E-cadherin,

CK7, CD15 and EMA. The other tumor adjacent the oncocytoma had a distinctive

morphology was confirmed on subsequent immunohistochemistry. The tumor

consisted of large cells with moderate to abundant cytoplasm and hyperchromatic

nucleus with prominent nucleoli, showed positive reaction with CK7, EMA and

synaptophysin was compatible with large cell neuroendocrine carcinoma.

Although tumor-to-tumor metastasis (TTM) is a rare phenomenon, being aware

of the tumor-to-tumor metastasis phenomenon and considering this possibility is

likely to lead to a correct diagnosis, particularly in patients with a history of a

second malignancy

Key Words: Lung Carcinoma , Oncocytoma, Tumor-to-tumor metastasis,

17. Extragastrointestinal Stromal Tumor of Kidney in

Nontransplant Recipient Patient : The First Case

İn The Literature

Metin KARAKOK1, Omer Faruk DIZIBUYUK1, Ismail KARLIDAG2, Zehra BOZDAG1

1Gaziantep University, Department of Pathology, Gaziantep, Turkey

2 Mehmet Akif Inan Research and Education Hospital, Department of Urology, Sanlıurfa,

Turkey


Gastrointestinal stromal tumors (GISTs) are the most common primary mesenchymal

gastrointestinal neoplasms that is most commonly found in stomach (40–70%), small

intestine (20–40%) and colorectum (5– 15%). It originates from the interstitial Cajal cells

which present throughout the wall of gastrointestinal (GI) tract and coordinate

peristalsism. While the majority of GISTs develop in the GI tract, in rare cases they may

also be found in extragastrointestinal tissues. This type of GIST is known as an

extragastrointestinal stromal tumor (EGIST). The occurrence of most EGIST is related

to the metastasis of primary GIST There have been several reported EGIST cases such

as in mesentery, omentum, retroperitoneum, pleura, lungs, vagina, liver and spleen .

A 58-year-old man, operated because of left renal mass in an external hospital. After

the microscopic examination the tumor diagnosed as malign mesenchymal tumor and

referred to our pathology dapertment for detailed examination and diagnosis. The

microscopic examination of HE sections obtained from paraffin embedded blockes

showed spindle cell neoplasm and immunohistochemical (IHC) examination showed

positive expression with CD117(c-kit), CD-34, Vimentin and Dog-1. Actin expression

was detected in isolated cells. There was no expression with S-100, Desmin, and

Pancytoceratin. Based on the histomorphologic and IHC findings, the tumor was

diagnosed as EGIST.

There was only 3 reported cases in the literature who were all kidney transplant

recipients. To our knowledge, this is the first case reported of EGIST arising in the

kidney which has no history of transplantation.

Key Words: EGIST, GIST, Kidney

18. Collision Tumor of the Stomach: A Case of an

Adenocarcinoma and a Malignant Lymphoma

Metin KARAKOK, Omer Faruk DİZİBUYUK, Zehra BOZDAG

Gaziantep University, Department of Pathology, Gaziantep, Turkey

Adenocarcinoma takes up about 95% among malignant tumors of the stomach,

and the remainings are mostly lymphomas, being less than 5%. The majority of

lymphomas are B cell lymphomas, and the most common types are low-grade B

cell lymphoma of mucosa-associated lymphoid tissue and diffuse large B cell

lymphoma (DLBL) . A collision tumor of the stomach is a rare event. The

occurrence of a collision tumor in the stomach, consisting of adenocarcinoma and

malignant lymphoma, is extremely rare.

A 66-year-old woman with the diagnosis of gastric adenocarcinoma, underwent

total gastrectomy.On macroscopic examination, a polipoid mass with 1 cm

diameter was detected in antrum. The microscopic examination of the mass


revealed two distinct tumor in same area.There were poorly differantiated gastric

adenocarcinoma areas showed positive reaction with Pancytoceratin and EMA,

and the other tumor beside adenocarcinoma consisted of atypical large lymphoid

cells with diffuse growth pattern.These lymphoid cells showed positive reaction

with CD20,CD79a,Bcl-2,Bcl-6,CD10 and MUM-1. Based on this morphologic and

IHC findings, the tumor was diagnosed as a collision tumor consisting of

adenocarcinoma and DLBCL.

In conclusion; all the malignant tumors should be carefully examined for the

second (collision) tumor before the diagnosis.

Key Words: Collision tumor, DLBCL, Gastric adenocarcinoma.

19. Detection of gene expression in sentinel

lymph node of primary breast cancer patients

from Iran

Prof Abolfazl Movafagh1* , Maryam Haji SeyedJavadi 1 , Shahrzad Soleimani2, Narjes

Mehrvar4, Shohreh Alizadeh Shargh3, Neda Mansouri1, Aliasghar Keramatinia4,

Mortazavi-Tabatabaei Seyed Abdol Reza5

1*Department of Medical Genetics, Shohada hospital, Research Center, School of Medicine,

Shahid Beheshti University of Medical Sciences, Tehran, Iran.2 Department of Molecular

Genetics, Institute of Basic Science, Shahrekord Islamic Azad University; 3 Medical

Laboratory Science Department, Midwifery-Nursing Institute, Islamic Azad University of

Chalous Branch, Chalous; 4 Cancer Research Center, Shahid Beheshti University of Medical

Sciences, Tehran; 5 Proteomics Research Center, School of Paramedical Sciences, Shahid

Beheshti University of Medical Sciences, Tehran

Email [email protected]

Background: Sentinel lymph node (SLN) micrometstasis detection improves outcome

for breast cancer follow up procedure. The aim of the present study was to identify gene

profiles that accurately predicted the outcome of breast cancer patients.

Materials and Methods: In this study we examined in 50 Sentinel Lymph Node (SLN)

biopsy present of small number of cancerous cell between breast tumor and Axillary

lymph nodes for the expression of 3 genes MUC1, BUB1b and NEK2 using quantitative-

PCR. Also clinical verification for recurrence to distant organs was performed. Three

gene signature were confirmed based on tumor’s stage, grade, ER status, using

conditional logistic regression.

Results: Based on this findings, the negative reported lymph nodes for metastasis, had

micro metastasis in significant values. There was a significant difference between

normal and cancer samples in 3 gene expression marker and also there was meaningful



relationship between three gene expression with tumor’s grade, stage according to

progression of tumor.

Conclusions: A novel gene expression signature predictive of micro metastatic patients

was evaluated. In this assessment, relationship between these gene with tumor’s

features that finding clear role for these genes with tumor’s outcome, needs to be

established.

Keywords: Breast cancer, Gene signature, Sentinel Lymph node, Iran

20. A case of a male with a sigmoid adenocarcinoma

which accompanied with an isolated unilateral

adrenal metastasis:

Wassim ALMAHLI 1, Ilyas BASKONUS 1, Alper AYTEKIN 1, Latif YILMAZ 1

1: The General Surgery Department, Gaziantep University Hospital, Gaziantep, Turkey.

Although the liver and the lung are the main metastatic sites, the incidence of

adrenal metastasis from colorectal cancer in autopsy ranges from 1.9% to 17.4%

according to different reports.The most common primary tumours that

metastasize to the adrenal glands are the lung,kidney,breast,and rarely the

colorectal cancer.The alone adrenal metastasis due to colorectal carcinoma is very

rare. Due to their rarity, on the basis of international literature and our experience

of adrenalectomy could represent the current“gold-standard”therapeutic

approach. In this report we explain the case of a patient who presented with a

sigmoid cancer, and one side adrenal metastasis without any other different

distant metastasis.The solitary adrenal metastasis of sigmoid cancer is a

comparatively rare condition especially coupled with metachronous contralateral

adrenal metastasis, according to our review of the literature. And it is difficult to

be diagnosed because it doesn't have any characteristic symptoms.

Key words: sigmoid adenocarcinoma-adrenal metastasis-colorectal cancers.

21. The descriptive epidemiology of the Human

papillomavirus attributable cancers: An

international comparison of incidence, and

mortality

Author: Professor Zoubida Zaidi

University of Setif, Algeria


Introduction: Human papillomavirus (HPV) attributable cancers (HPVAC) are a major

worldwide public health concern, with much higher burden in less developed regions.

Cervical cancers represent 530.000 new cases per year and account for the vast majority

of all HPV-attributable cancer cases worldwide. HPV also causes anal, vaginal, vulvar,

penile, and oropharyngeal cancer. Over 90% of the HPV-related ones are related to

HPV16, -18. The HPVAC are dominated by cervical cancer in the developing world,

where cervical cancer screening is limited.

Aim: this communication presents the latest international descriptive epidemiological

data for HPVAC including incidence and mortality in the worldwide.

Methods: the incidence and mortality statistics presented for HPV attributable cancers

worldwide were taken from* the International Agency for Research on Cancer IARC,

the Cancer Incidence in five Continents Vol XI , * GLOBOCAN database, 2012 and the

finding of the Global Burden Diseases study 2015. Data are shown separately for cervix,

other anogenital tract and head and neck cancers

Results: HPVAC represent the second most common infection-related cancers

worldwide with 4,5% of all cancers (630.000 new cancer cases by year) are attributable

to HPV with 8,6% in women and 0,8% in men. Attributable fractions in women ranges

from <3% Australia/New Zealand and the USA to >20% in India and sub-Saharan Africa.

-Cervix accounts for 83% of HPV-attributable cancer, two-thirds of which occur in less

developed countries.

-Other HPV-attributable anogenital cancer includes 8,500 vulva; 12,000 vagina; 35,000

anus (half occurring in men) and 13,000 penis. Anogenital cancers are mainly located in

Latin and Northern America and Australia but a few are also found in Europe and sub-

Saharan Africa. --The head and neck, HPVAC represent 38,000 cases of which 21,000

are oropharyngeal cancers occurring in more developed countries. The incidence of

HPV-attributable head and neck cancer is relatively high over 1.25 per 100,000 are

located in Northern America and Europe.

Conclusions: the preponderant burden of HPV16/18 and the possibility of cross-

protection emphasize the importance of the introduction of more affordable vaccines

in less developed countries.

22. Synthesis of Novel Chalcone Analogs for Triple

Negative Breast Cancer Therapy

Dana Elkhalifa1, Feras Alali1, Ala-Eddin Al Moustafa2,3,4 & Ashraf Khalil1

1College of Pharmacy, 2College of Medicine and 3Biomedical Research Center, Qatar

University, Doha, Qatar; and 4Oncology Department, McGill University, Montréal, Canada


Introduction: Triple negative breast cancers (TNBCs) are aggressive tumors that

do not express human epidermal growth factor receptor 2, estrogen and/or

progesterone receptors. Therefore, TNBC patients have tremendously poorer

prognosis and do not respond satisfactory to current chemotherapeutics.

Chalcone is an attractive molecule for drug synthesis due to its promising

pharmacological activities in a range of diseases including cancer.

Objectives: The aims of this study are to design, synthesize and biologically

evaluate the anticancer activities of novel chalcone-based compounds for the

treatment of triple negative breast cancers.

Methods: Chalcone analogs were synthesized and purified followed by chemical

characterization studies. The molecular anticancer activities were studied in vitro

on noninvasive and invasive breast cancer cell lines. The effect on angiogenesis of

the most promising compounds were studied in vivo using chicken embryos.

Results: Fifteen compounds were synthesized so far. The screening of the first six

compounds (DK1-DK6) revealed that compounds DK2 and DK5 had significantly

inhibited cancer progression. They suppressed colony formation in MCF-7

noninvasive and MDA-MB-231 invasive breast cancer cell lines as was

demonstrated by the soft agar assay. In addition, compound DK5 inhibited

angiogenesis in treated chicken embryos. It had also caused the highest inhibition

of cells proliferation in the MCF-7 cells followed by DK6 at 48 hours posttreatment

(63.1% and 63% inhibition, respectively). The activity of DK5 was significantly

reduced in the MDA-MB-231 cells (34.1% inhibition). In contrast, DK2 caused

significant cells proliferation inhibition (59.8%) in the MDA-MB-231 cell line which

resembles TNBC.

Conclusion: Taken together, our data provided an evidence that some of the

screened compounds (DK1-DK6) may serve as promising therapeutic agents for

TNBCs. The anticancer screening shall be continued and performed for the rest of

the compounds (DK7-DK15).

Gaziantep: The City Gaziantep is one of the oldest continuously

inhabited cities in the world, as traces of

settlement in Gaziantep go back to the 4th

millennium BC. The city fortress, the

Ravanda citadel

is located at the center of the city Gaziantep became the economic

center of the southeastern and east

Turkey. Its industrial area comprises

four percent of the Turkish industry in

general and particularly for olive oil

based soaps and machined carpets.

In addition to several museums in the city, there are various attractions that range from historic

landmarks to shopping centers and entertainment areas. Gaziantep hosts the largest enclosed

shopping centers in the region, Sanko Park, in addition to the Gaziantep Zoo, the home of a

variety of animals and rare birds.

Other important attractions include: The Boyaci Mosque, Sirvani Mosque, Omeriye Mosque,

Eyupoglu Mosque, Kendirli Chruch, Pisirici Kastel (a water fountain built below ground), Tahmis

Coffee House (A coffee house built in 1635-1638 by Mustafa Aga Bin Yusuf) and of course in

addition to the historical bazaars such as Zincirli Bedesten.

8

Gaziantep: Where Old and New intertwine

1. Gaziantep University Tourism Hotel

2. Gaziantep University

3. Gaziantep Citadel

4. Pisirici Kastel

5. Omeriye Mosque

6. Tahmis Coffee House

7. Sanko ParkBayazhan

8. Gaziantep Kent Museum

1

v

2

v

7

3

v

4

v

6

v

5

v

4

v

7

5

6

8

The 7th annual meeting of the

MEACR was realized thanks to

Gaziantep University in collaboration with the

College of Medicine of

Qatar University

the 7th annual meeting of the middle-eastern association for cancer...

Documents